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CHAPTER 1. INTRODUCTION
Zwitterionic polymers possess a positively charged group and a negatively charged
group in each repeating unit1. The specific poly-salt-like structure rendered
zwitterionic polymer a super-hydrophilic nature2-3. These years, intense studies have
been focused on the unique properties and potential applications of zwitterionic
polymers in biomedical fields such as drug delivery4-5, implantable devices6-7, and
tissue engineering8-9.
Common

zwitterionic

materials

include

poly-phosphobetaine

(PPC),

poly-sulfobetaine (PSB), and poly-carboxybetaine (PCB). PSB materials such as
poly(sulfobetaine methacrylate) (PSBMA) have been wildly studied as medical device
coating10 and marine coating applications11. PSB materials are generally easy to
synthesize with low expense. However, the sulfonic acid groups on PSB polymer
have shown to exhibit toxicity for cells in biomedical applications12. Different from
PSB materials, the PPC materials are considered to be biomimetic since it had a
phosphorylcholine head group in each repeating unit, which is found abundant in the
cell membrane13. Nevertheless, the synthesis procedure of phosphobetaine
monomers, such as 2-methacryloyloxyethyl phosphorylcholine (MPC), is complex
with associated high expense14.
The PCB has been studied intensively for structural and chemical properties15.
Compared with PPC and PSB, PCB retains their advantages and shows further unique
properties that cannot be achieved by other types of zwitterion materials. Surface
plasma resonance (SPR) sensor study exhibited that gold substrate coated with PCB
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polymer was able to achieve super-low fouling of protein binding (<0.3 ng/cm2) in
complex physiological environments16-17. In addition, the PCB materials can be
regarded as biomimetic since the carboxy-betaine chemical group is very similar to
the glycine betaine, which is one of the solutes in human body fluid that is crucial for
regulating the osmotic pressure of cells and the estimated daily glycine betaine
intake of an adult from 0.1 to 2.5 g18. PCB materials have not been found to be toxic
in both in-vitro and in vivo animal studies19. Furthermore, the carboxyl group of PCB
can be used to immobilize functional biomolecules or fluorescent dye molecules via
simple 1-ethyl-3-(3-dimethyl-aminopropyl)-carbodiimide and N-hydroxy-succinimide
(EDC-NHS) chemistry to extend the functionality of the material20. Lastly, the
synthesis of the PCB monomer such as carboxybetaine methacrylate (CBMA) and
carboxybetaine acrylamide (CBAA) is typically a one-step reaction with cheap
reagents involved21.
When using zwitterionic polymers to modify materials for a variety of applications,
a common challenge exists that most zwitterionic monomers and polymers are
highly polar and not able to be dissolved in organic solvents. When the materials to
be modified are hydrophobic, which is frequently the case, it is hard to find an
appropriate solvent to co-dissolve the zwitterionic monomer/polymer and the
hydrophobic materials to conducting the modifying reaction22. PCB is unique that it
has a precursor form, CB-tBu (tertbutyl ester of CB monomer), that could be
dissolved in many organic solvents such as DMF and acetonitrile, and after the
modification reaction, PCB can be re-generated by hydrolyzing the tBu ester groups.
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This strategy greatly broadens the applications of PCB materials in many application
scenarios4.
Based on the unique super-hydrophilic property, the zwitterionic polymer
materials had been studied for their potentials in various applications. Surfaces
coated with zwitterionic polymers were found to effectively reduce more than 95%
of the adhesion of the protein and microorganism in physiological environments
such as blood plasma17 and seawaters11. Meanwhile, nanoparticles such as PLGA
nanoparticles and liposome modified by zwitterionic PCBMA polymers were found to
show unprecedented colloidal stability and increased circulation time in blood23.
Zwitterionic polymers stabilized nanoparticles have shown great improvement in
diagnostic and therapeutic performance compared with nanoparticles stabilized by
the commonly used polyethyleneglycol (PEG), the golden standard for nanoparticle
modification24.
In addition to anti-biofouling and nanoparticle stabilizing properties, recent
research revealed many great properties of PCB materials for biomedical
applications. It was found that a pure PCBMA hydrogel implant was able to resist
foreign body reaction, which was rarely reported in other common biomaterials such
as polyethylene glycol (PEG), alginate and Poly-hydroxyethyl-methacrylate (PHEMA)6,
25.

Meanwhile, other research reported that a non-fouling PCBMA hydrogel surface

enabled stem cells to retain their stem cell phenotype and multipotency,
independent of differentiation-promoting media, cytoskeletal-manipulation agents,
and the stiffness of the hydrogel matrix. The differentiation of stem cells can be
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controlled by altering the fouling moieties on the PCBMA gel surface8.
The focus of this thesis is to study the potentials of the zwitterionic PCB materials
in solving several key challenges in various applications as stabilizing materials for
nanoparticles, hydrogels, and surface coatings, respectively. Specifically, this thesis
involves the work of a one-step synthesis of zwitterionic polymer modified carbon
nanoparticles, pancreatic islets encapsulation by PCB hydrogel materials and
subsequent transplantation to achieve long-term diabetic reversal effect, and a
durable zwitterionic PCB polymer coating for various substrates to resist long-term
biofilm formation. These subjects are introduced separately in the following
paragraphs.
1.1 Zwitterionic polymers for nanoparticles surface modification
Anti-fouling polymer materials, especially zwitterionic materials, had been utilized
to modify nanoparticles to improve their colloidal stability, the key to maintain the
unique properties of nanoparticles5,

26-28.

Super-hydrophilic zwitterionic polymer

chains attract a dense layer of water molecules to separate nanoparticles from
aggregation29. Nevertheless, nanoparticle modification with zwitterionic materials is
not straightforward. Since most zwitterionic materials were unable to be dissolved in
organic solvent, conjugation of zwitterionic polymers to hydrophobic nanoparticle
surface was usually hard and involved complex procedures4 (usually involved 5-6
steps). Easy modification of nanoparticles by super-hydrophilic polymers remained a
grand challenge in this field. In this work, for the first time, we directly made
ultra-stable nanoparticles from zwitterionic polymers by the facile one-step
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microwave method. The resulting nanoparticle showed superior colloid stability in
bio-relevant media and even at the freeze-drying conditions. This work will be
discussed in Chapter 2.
1.2 Zwitterionic hydrogel for islet encapsulation
Polymer hydrogel materials had long been studied as a promising solution for Type
1 Diabetes (T1D) by delivering insulin independence without immunosuppressant30-33.
Polymer hydrogel layer was able to provide protection for transplanted from the
attack of the host’s immune system and are believed to control blood glucose in a
long term34-35. The major challenge is that current encapsulation materials can well
protect the islets inside, but they became the target of the host’s immune system
instead36. A process called foreign body reaction can virtually happen on all existing
implanted polymer hydrogel37, which would suffocate islets by cutting off the oxygen
transport from blood and also hinders glucose/insulin transport for the implant to
achieve therapeutic function38. It remained a challenge for hydrogel materials to
sustain long-term blood accessibility39. Our research demonstrated that a
zwitterionic material based hydrogel system was able to perfectly integrate with host
tissues and remains instantly accessible by circulating blood even after long-term
implantation at least for five months. It was further demonstrated that with such
perfect body integration, blood nutrients can be easily transported to the hydrogel
implant to support the survival and maintain the blood glucose control ability of islet
cells. The hydrogel/ rat islet constructs have been s.c. implanted to
non-immunosuppressed STZ-mice, and the preliminary result shows insulin
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independence of the diabetic mice for at least two months. These works will be
described in Chapter 3.
1.3 Durable zwitterionic coating for long-term biofilm resistance
Zwitterionic polymer coatings had been demonstrated to effectively resist
microorganism adhesion40-44. The super-hydrophilic anti-fouling polymers prevent
the attachment of single bacteria cell onto the coating and therefore prevent the
formation of biofilm45. PCB materials were proved to be efficient in resisting 95%
Pseudomonas aeruginosa and Staphylococcus epidermis bacteria adhesion and
reducing the formation of biofilm46. However, unlike hydrophobic polymer coatings,
super-hydrophilic zwitterionic polymer coatings drastically tend to dissolve into water
environment47. This leads to gradual exposure of the coated surface over time and
hinders the use of zwitterionic coating in applications that require long-term
durability48. Therefore, improving the durability and toughness of zwitterionic
polymer coating could lead to the success of long-term biofilm resistance. We
developed several methods to improve the toughness and durability of zwitterionic
coatings and achieved long-term bacteria biofilm (gram-negative, gram-positive and
fungi) resistance on various substrates for up to one month challenge in the bacteria
culture media. These works will be discussed in Chapter 4 and 5.
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CHAPTER 2. ONE-STEP SYNTHESIS OF ZWITTERIONIC POLYMERS STABILIZED
CARBON NANOPARTICLES
2.1 Introduction
Zwitterionic polymers had been utilized to modify hydrophobic core to render
nanoparticle with colloid stability, especially in bio-related environment. However,
these methods were either involving complex chemical synthesis or low in efficiency
due to unpredicted NP surface environment. In this Chapter, we designed novel
strategy to make ultra-stable core-shell nanoparticles directly from zwitterionic
polymer through one step reaction, completely different from any existing methods.
Resulting nanoparticles were stable in bio-related environment and even harsh
freeze-drying condition. This work provides a completely new concept to achieve
making stable nanoparticles through green chemistry and was expected to inspire
future functional NPs to be developed.
Colloid stability is crucial for nanoparticles (NPs) to remain nano-effects in various
functioning media. NPs with hydrophobic core suffered from aggregation problem
seriously, especially in bio-related media, which hindered their applications in drug
delivery and imaging49-52. Typically, anti-fouling polymers, capable of resisting
nonspecific protein adsorption, were utilized to modify a NP core to prevent it from
aggregation53. This modification has been done through various methods, e.g., via
surface adsorption54-55, chemical conjugation4 (e.g., the commonly used “graft-to”
method to modify the surface with anti-fouling materials such as PEG56-57), and
particle encapsulation in polymeric micelles58-61, to produce hydrophobic
core-anti-fouling polymer shell NPs. These methods however either involved complex
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chemical synthesis procedures62-63 or were low in efficiency due to unpredicted NP
surface environment64. As an alternative method to these complex modification
procedures, we explore the feasibility to make the NPs directly from anti-fouling
polymers with superior colloid stability. To the best of our knowledge, a hydrophobic
NP stabilized by anti-fouling polymers made purely from the polymer itself has not
been reported.
Inspired by the facile one-step microwave method to fabricate carbon
nanoparticles65-66, for the first time, we directly made ultra-stable NPs from
zwitterionic polymers with part of the polymer chain carbonized into the
hydrophobic core and the rest of the intact polymer as the hydrophilic stabilizing
shell. Zwitterionic polymers were chosen, since they have demonstrated their
excellent anti-fouling properties in resisting non-specific binding from proteins, cells
and microorganisms67. NPs previously modified with zwitterionic polymers showed
good colloid stability and long-circulation time in blood23. The synthesized
carbon-core polymer-shell structure was confirmed using NMR and TEM. The directly
made NPs were found to be ultra-stable in bio-relevant media and even the harsh
freeze-drying conditions (with no cyro-protectant in presence), note that most
existing NPs could not survive from such extreme lyophilizing conditions.
2.2 Materials and Methods
2.2.1 Materials
Methacryloyloxyethyl phosphorylcholine (MPC 97%), 2-Methacryloyloxy-ethyl
-dimethyl 3-sulfopropyl ammonium hydroxide (SBMA 97%), Tert-Butyl bromoacetate
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(98%), 2-(Dimethylamino) ethyl mathacrylate (DMA 98%), Amberlite IRN78 hydroxide
form, Quinine hemisulfate salt monohydrate (98%), Acetone (99.5%), Phosphate
buttered Saline tablet (PBS), Albumin from bovine serum (BSA 98%) and Fibrinogen
from bovine plasma (65-85%) were purchased from Sigma-Aldrich, St. Louis, MO.
Ethyl Ether Anhydrous (99.9%) and Boric Anhydride were obtained from Fisher
Chemical. Co. Acetonitrile anhydrous (99.9%) was purchased from ACROS Organics.
B-Propiolactone (95%) was supplied by Wako Pure Chemical Industries Ltd.
Deuterium Oxide (D2O 99.9%) was obtained from Cambridge Isotope Laboratories,
Inc. USA. PD-10 desalt columns were purchased from GE Healthcare, UK. Boric
Anhydride was utilized to dry acetone and all other chemicals were used without
further purification.
2.2.2 Synthesis of PSB NPs, PMPC NPs, PCB-2 NPs
5 mg photo-initiator was added to 5 ml degassed DI water and 100 mg SBMA, MPC,
CBMA-2 (synthesis as previous report) monomer was dissolved 0.5 ml photo-initiator
solution. Polymerization was initiated by exposing the solution under UV (365 nm, 6
W) for 2 minutes with stirring. Then resulted polymer solution was diluted to 2.5 ml
and went through salt filter column (cutoff molecular weight 2000) to remove
residue monomer and initiator. Pure polymer (Mw 10k) solution was poured into a
flask and the flask was set in the center of a domestic microwave oven. After heating
under 1200 W for 5 minutes, light brown substance emerged in the bottom of the
flask. 10 ml DI water was added and stirred for 1 h. Resulting solution was
centrifuged at 4400 rpm for 10 min to remove the insoluble, yielding a clear light
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brown NPs solution with florescence under UV. The general yeild was 56.65%.
2.2.3 Synthesis of PCB-1 NPs
CBMA t-butyl monomer was synthesized as previous report4. 200 mg of CBMA tbul
monomer was hydrolyzed in 2 ml TFA for 5h. TFA solution was dropped in anhydrous
ethyl ether to remove TFA and precipitate CBMA-1 zwitterionic monomer. After
vacuum dried, monomer was dissolved in 0.5 ml photo-initiator solution described
above in ice bath. Basic resin was used to adjust solution pH to 7 and the yielding
solution was exposed under UV to initiate polymerization. The resulting PCB-1 was
similarly purified and made into NPs as described in the last section.
2.2.4 NPs purification
2 g sucrose,was dissolved in 10 ml DI water to prepare sucrose stock solution. 1.4
ml sucrose solution was added to a centrifuge tube and 0.1 ml NPs raw solution was
slowly added to obtain a well-defined NP region on the top of sucrose solution.
Centrifuge the tube for 1 h at 15000 rpm at room temperature and expose the tube
to UV. NP region in the sucrose column showed blue florescence and was collected
using a pipette. The collected solution will go through a PD-10 column to remove
contaminated sucrose.
2.2.5 Nanoparticle Characterization:
The morphology and microstructure of the PMPC NPs and PCB-1 NPs were
examined by transmission electron microscopy (TEM) on JEOL 2010 TEM with LaB6
Filament Gun (JEOL Ltd. Tokyo, Japan) under accelerating voltage of 200 kV. Purified
sample solutions were dropped onto a 300-mesh copper grid coated with a lacy
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carbon film to make TEM sample. Nuclear Magnetic Resonance H1 spectrum of
zwitterionic polymer and purified NPs were conducted on Varian Mercury-400 MHz
NMR. Polymer and purified NPs were lyophilized and dissolved in Deuterium Oxide
(D2O). Molecular weight of the MPC and CB-1 polymer are determined by a Waters
Alliance 2695 Separations Module equipped with a Waters Ultrahydrogel Linear
column and a Waters 2414 reflex detector. The mobile phase was PBS buffer solution
at a flow rate of 0.7 ml/min at 35 °C. Poly(ethylene oxide) from Polymer Laboratories
were used as standards. UV absorption of NPs was conducted on a Multiskan GO
UV–Vis Spectrophotometer (Thermo Scientific, USA).
2.2.6 Fluorescence Property measurement
The maximum absorptions were 354 nm for PMPC NPs and 367 nm for PCB-1 NPs.
Maximum emissions are 436 nm for PMPC NPs and 455 nm for PCB-1 NPs. Quantum
yield of the PMPC NPs and PCB-1 NPs were determined by comparative method.
Quinine hemisulfate in 0.1 M H2SO4 was utilized as the standard whose QY was
reported to be 54%. The integrated fluorescence intensity is the area under the PL
curve in the wavelength range from 380 to 650 nm with 365 nm excitation. Absolute
values were calculated according to the following equation:

Where ST denotes the standard, Grad is the gradient from the plot of integrated
fluorescence intensity vs absorbance, and η is the refractive index of the solvent. To
prevent the re-absorption effect, absorbance in the 10 mm fluorescence cuvette
should never exceed 0.1 at the excitation wavelength. The resulted QY for PMPC NPs
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and PCB-1 NPs were 8.92 ± 0.60 % and 7.02 ± 0.59 %, respectively.
2.2.7 MTT cytotoxicity assays
The cytotoxicity of the PMPC NPs and PCB-1 NPs was determined by MTT assay.
NIH/3T3 Fibroblast were grown in 96-well plates in full Dulbecco's Modified Eagle's
Medium and 10% FBS under 5% CO2 at 37 °C to allow 80-90% confluence. For each
well, cells were washed with PBS and incubated with 200 μl full medium containing
varied concentration of PMPC NPs, PCB-1 NPs and CA NPs for 24 h. Cells were
washed with PBS to remove NPs and incubated with 100 μl full medium plus 50 μl of
12 mM MTT stock solution for another 4 h. Then, MTT containing medium was
replaced with 150 μl DMSO to dissolve the formed crystal at 37 °C for 10 min.
Absorbance (Abs) was measured at 570 nm with pure DMSO as the blank reading.
Cells with no NPs incubation were used as the controls and cell viability upon NPs
treatment was estimated in triplicate: cell viability (%) = Abssample / Abscontrol x
100.
2.3 Result and discussion
The synthetic route to core-shell zwitterionic NPs composed of one single step,
microwave heating of zwitterionic polymers (Figure 2-1). Typically, Zwitterionic
polymers were synthesized through UV initiated polymerization of respective
monomers. Then, a beaker containing 100 mg of zwitterionic polymer (Mw 8-10 KDa)
in 5 ml DI water was placed at the centre of the rotation plate of a 1000 W
microwave oven and heated for 5 minutes. As water evaporated, light brown
substance was obtained in the bottom of the beaker. This microwave method is
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simple, facile and green, however, there are several obstacles to overcome before
obtaining the targeted core-shell zwitterionic NPs.
The primary challenge is that microwave oven heating can’t be easily controlled
and resulting polymer NPs are contaminated with unreacted polymers and have
broad size distribution (PDI > 0.6 as measured by dynamic light scattering, DLS).
Conventional purification methods such as centrifugation, filtration, or dialysis can’t
effectively remove the contaminating polymers or obtain homogeneously sized NPs.
We found a sucrose gradient centrifugation method can be effective to purify the
rough products68. NPs migrate under the centrifugation force with their migration
pattern retained by sucrose while linear free polymers barely moved and stayed on
top of the sucrose column. This was confirmed by control experiment where free
polymer solution alone was loaded on top of the sucrose column and DLS results
showed no polymer presented in the NPs layer. By exposing the centrifuge tube to
UV light, polymer protected NPs can be visualized and retrieved (fluorescent
property will be discussed below). Further removal of sucrose was achieved by using
a PD-10 column and highly purified polymer protected NPs (free from unreacted
polymers with narrow size distribution, diameter < 30 nm, PDI < 0.15) can be
obtained.
The next challenge we met is that zwitterionic polymer chosen should stand high
temperature of the microwave heating reaction. While part of the polymer
carbonized into the NP core, the other part of the polymer should be thermally intact
maintaining the anti-fouling zwitterionic structure. Our initial testing with
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poly(sulfobetaine) (PSB)69 and poly(carboxybetaine)-2 (PCB-2) (Table 2-1), two
common zwitterionic polymers we previously worked on, was not successful; the
obtained NPs were positively charged as indicated by zeta-potential measurement in
water. This could be explained by the thermo-instability of SB and CB-2 units; when
heated at high temperature, the quaternary amine group tends to undergo
“elimination reaction” splitting into a tertiary amine and an acrylic group70. The
resulting NPs thus showed positive net charges due to the protonated tertiary
amines

formed

on

the

-(2-methacry-loyloxyethyl

protecting

polymer

phosphorylcholine)

shell.

By

(PMPC)71-74

contrast,

poly

and

poly

-(carboxybetaine)-1 (PCB-1)75 polymers were found to render resulting NPs with
zwitterionic property, as characterized by a slightly negative zeta potential of the
resulting NPs. It should be noted that their parent zwitterionic polymers gave similar
negative zeta potentials in the control experiment (Table 2-1). Among four kinds of
polymer derived NPs, only PMPC and PCB-1 NPs were chosen for further study due
to their zwitterionic shell nature.
It was hypothesized that the zwitterionic polymer was partially burnt into the
carbon core while the remaining part forming a super-hydrophilic shell. The structure
of the purified zwitterionic NPs was further examined using transmission electron
microscopy (TEM) and nuclear Magnetic resonance H1 (NMR). Organic molecules are
known for their carbonization under microwave heating conditions76-77. Carbon core
structure for PCB-1 NPs and PMPC NPs could be detected under the TEM (Figure 2-2).
Average core diameters for PMPC NPs and PCB-1 NPs were 12 nm and 11 nm,
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respectively. NMR results (Figure 2-3) showed a perfect match between the peaks of
polymer shell of NPs and the parent free polymers, indicating that the protecting
polymer structure remained intact on the NP surface.
For potential biological applications, NPs have to be stable in complex
environment where bio-elements (e.g., proteins) were present. It is expected that
the synthesized zwitterionic NPs are well protected from aggregation by the
zwitterionic shell in the bio-related media. As non-zwitterionic polymer NP controls,
we synthesized CA NPs, from citric acid and ethylenediamine through the same
microwave method (a well-established fluorescent NP system with ultra-high
quantum yield78), and purified it via the same sucrose centrifugation procedure. The
resulting CA NPs had slightly negative zeta potential (-1.78 mV), similar to
zwitterionic polymer stabilized NPs, but were lack of a zwitterionic polymer shell
surface. For colloid stability testing, purified PMPC NPs, PCB-1 NPs and CA CNPs (size
< 30 nm PDI < 0.18) were placed in PBS (phosphate buffered saline, salt
concentration 153 mM), PBS solution of 5 wt% bovine serum albumin (BSA) and PBS
solution of 5 wt% fibrinogen from bovine plasma. The sizes for NPs were measured
as a function of time (Figure 2-4(a) and Figure 2-5). No obvious size increase
appeared in any of the zwitterionic polymer NPs groups while CA NPs aggregated
drastically. It is a general trend that particles tend to be less stable in high salt
concentration solution79. Zwitterionic PCB-1 NPs, however, retained its original size in
a solution with salt concentration as high as 500 mM in a 40-min study (i.e.). CA NPs
by contrast doubled its size overnight even in DI water with zero ionic strength.
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Long-term stability study (Figure 2-4(b)) showed that both PMPC NPs and PCB-1 NPs,
after one week incubation in PBS, have no significant size increase while CA NPs
continuously aggregated.
Lyophilization, a necessary procedure for NP storage and precise weighing,
introduces harsh interaction among individual NPs, causing aggregation that could
not be segregated even under sonication. To the best of our knowledge, NPs even
protected by anti-fouling polymers are very rare to survive from lyophilization
induced aggregation. We used lyophilization conditions to further push the limit of
stability performance of the zwitterionic core-shell particles. PMPC NPs, PCB-1 NPs,
and CA NPs were lyophilized without adding any cryoprotectant and re-dissolved in
DI water and their sizes were measured using DLS (Figure 2-6). CA NPs aggregated
substantially after freeze-drying while zwitterionic NPs survived such harsh condition
by maintaining the particle size. We have previously observed that PCB-1 protected
PLGA NPs can sustain the original size through lyophilization, while other NP
protecting technology (such as PEG-PLGA) can’t but require the addition of
cyro-protectant (e,g., 10% sucrose)80. It was believed that zwitterionic polymers
strongly bind water molecules to prevent hydrophobic interactions among carbon
cores in this case, and keep them apart even in a highly dehydrated environment22.
With excellent stability, both in bio-relevant media and harsh freeze drying
conditions, we demonstrated the effectiveness of our strategy to render NPs
ultra-stabile properties.
To verify that our way towards stable NPs do not cause cytotoxicity, MTT assay was
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conducted (Figure 2-7(a)). NIH/3T3 cells remained more than 85% and 80% viability
in PMPC NPs and PCB-1 NPs, respectively, at concentration as high as 10 mg/ml,
while CA NPs were toxic to cells (30% viability) at concentration as of 5 mg/ml. It is
worth-mentioned that the synthesized NPs had fluorescent property (Figure 2-7(b)).
Under UV excitation, Both the PCB-1 NPs and PMPC NPs exhibited blue light. It was
hypothesized that the fluorescent property was related to the core-shell structure,
which was previously reported as surface-passivation mechanism81. The fluorescent
property can lead to potential imaging applications of the resulting zwitterionic
NPs82-83.
In summary, we have demonstrated a novel strategy to make core-shell NPs with
superior stability directly and solely from anti-fouling zwitterionic polymers through
single step of microwave heating. Only those zwitterionic polymers, that are stable
through high temperature microwave heating can produce zwitterionic polymer
shell-carbon core NPs, which can be further purified through sucrose gradient
centrifugation. It was found that zwitterionic NPs maintained excellent colloid
stability in various bio-relevant media, and even under the harshest lyophilization
condition. With undetectable cytotoxicity, the new strategy will lead to ultra-stable
NPs for drug delivery and imaging application. We expect this green chemistry in
making ultra-stable NPs can inspire future functional NPs to be developed.
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Figure 2-1 Illustration of making carbonized core- zwitterionic polymer shell NPs
directly from zwitterionic polymers

Table 2-1 Structures for zwitterionic polymers involved and zeta-potentials for these
free polymers and the resulting NPs
Zeta-potential (mV)
Polymer
NP
(Parent)
(Synthesized)

n

Zwitterionic Polymer
Structures
O

PSB

O
N

-3.25±0.56

23.05±1.26
(cationic)

O

-4.77±0.32

18.73±2.06
(cationic)

N

-2.73±0.13

-4.33±0.80
(Zwitterionic)

-3.22±0.45

-4.75±0.78
(Zwitterionic)

O
S

O

O

n

*

O

O

PCB-2

N
O

n

*

O

PMPC

O
O

P

O

O

*

n

O

O

O
N

PCB-1

O
*

O
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Figure 2-2 (a) TEM image and statistic size distribution of PCB-1 NPs (scale bar: 100
nm) (b) TEM image and statistic size distribution of PMPC NPs (scale bar: 200 nm)
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Figure 2-3 (a) NMR spectra of parent CB-1 polymer and synthesized PCB-1 NPs, (b)
NMR spectra of parent MPC polymer and synthesized PMPC NPs
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Figure 2-4 (a) short-term and (b) long-term colloid stability of PCB-1, PMPC, and CA
NPs in PBS buffer
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Figure 2-5 Colloid stability (a) in BSA/PBS and (b) in fibrinogen/PBS buffer
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Figure 2-6 Colloid stability in freeze-drying condition of PCB-1 NPs, PMPC NPs and CA
NPs
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Figure 2-7 (a) MTT results of CB-1, MPC and CA NPs. (b) Fluorescent property of
zwitterionic NPs under UV (365 nm) excitation (Lift: PMPC NPs, Right: PCB-1 NPs)
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CHAPTER 3. ZWITTERIONIC HYDROGEL IMPLANT PROMOTES FUNCTIONAL BLOOD
VESSELS GROWTH AS GOOG AS NATURAL BODY SYSTEM
3.1 Introduction
In this chapter, we will describe the zwitterionic polymer hydrogel as the first
synthetic material ever known promoting functional neovascularization as good as
natural body system. A zwitterionic carboxy betaine containing hydrogel was found
to promote vascularization at the subcutaneous (s.c.) site to the same density level
as normal tissue, and to maintain that high-level vasculature for at least 6 months.
The newly formed blood vessels were perfused and they approached the implanted
zwitterionic gel surface as close as below 20 micrometers away. Consequently, the
zwitterionic hydrogel was highly accessible by circulating blood, even after 5 months
of implantation. This finding was highlighted by using zwitterionic hydrogel in
encapsulating islet of Langerhans for the treatment of Type 1 diabetes. The
zwitterionic

hydrogel

based

novel

system

remarkably

outperforms

the

state-of-the-art technology using alginate encapsulating materials at highly
challenging s.c. site.
Implantable devices based on biopolymers are wildly utilized in biomedical fields
such as cell encapsulation84-85, monitoring sensor coating86-87, controlled drug
release88 and tissue engineering89. Most of these applications require adequate body
fluid exchange, in which blood was the most crucial to enable the exchange of gasses,
nutrients, and metabolites between the blood and device, to sustain the survival of
tissue/cell grafts and achieve monitoring or therapeutic effect90-93. Blood accessibility,
therefore, is the key factor in determining successful implantation wherein a
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comparable density of blood vessel with normal tissue is considered to be ideal 94-95.
Nevertheless, most of the biomaterial implants could not escape from foreign body
reaction and blood accessibility was cut off soon after transplantation 96-97.
A number of researches had been done to increase blood vessel formation for
implanted materials. It was found that materials with microarchitecture were able to
promote neovascularization in surrounding area98, particularly at pore sizes of 30-40
µm99, but the resulting vessel density is still far below regular tissue level. Delivery of
growth factors (e.g., vascular endothelial growth factor and fibroblast growth
factors100-103), angiogenic genes104, and stem cells105-106 facilitates neovascularization
and has been studied for combinational delivery with cells in transplantation.
However, the blood vessels promoting effect was not able to be maintained when
the growth factors or gene were used out107. The high cost and potential safety issue
also hindered these methods from further advancement in applications.
Here, we developed hybrid hydrogel material containing zwitterionic carboxy
betaine (CB) moieties to solve the blood accessibility challenge. A zwitterionic
hydrogel material, after subcutaneous (s.c.) implantation, supports the growth of
new blood vessels to the same density level as naturally healed wound and healthy
tissue, and maintains such high-density vasculature for a long-term (up to 6 months,
the longest time point tested). The newly formed blood vessels were functionally
perfused, and the nearest vessels are within 20 μm distance from the implant
surface. Therefore, the zwitterionic hydrogel implants are highly blood accessible, as
indicated by the efficient accumulation of dye molecules on the hydrogel device,
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even after 5 months of implantation. This is the first synthetic material ever known
promoting functional neovascularization as good as natural body system. To
highlight the implication of this finding, the zwitterionic hydrogel was utilized to
encapsulate rat islets of Langerhans and s.c. implanted in diabetic mice. We
observed that islets encapsulated by state-of-the-art alginate materials (both high
guluronate and high mannuronate) failed to control blood glucose starting at day
~10 at the challenging s.c. implantation site, while zwitterionic hydrogel/islet
remarkably reversed diabetes through the entire 80 days of implantation. We expect,
with natural tissue-like blood accessibility, the zwitterionic hydrogel is a promising
platform to improve the long-term performance of most current implantable
devices.
3.2 Materials and methods
3.2.1 Materials
CBAA monomers were synthesized as previous reports108. PEGDA 10K was
purchased from Laysah Bio, Inc. (Lot# 136-18). HEMA monomers were obtained from
ACROS ORGANICS (New Jersey, USA). Sterile and low endotoxin alginate SLG20 and
alginate SLM100 were purchased from FMC Biopolymer. Evans Blue dye and
Fluorescein isothiocyanate-dextran (FITC-dextran) were obtained from Sigma-Aldrich.
(St. Louis, USA).
3.2.2 Synthesis of hydrogel materials
The PCBAA and PHEMA hydrogel were fabricated by UV initiation of monomer
solution of 50% in a weight ratio in the presence of 0.2% UV initiator
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2-Hydroxy-4′-(2-hydroxyethoxy)-2-methylpropiophenone (I-2959) and 1% crosslinker
(MBAA). Polyethylene (glycol) diacrylate (PEGDA) hydrogel was synthesized as
reported previously that PEGDA solution (10% in weight ratio) was crosslinked under
UV in the presence of 0.2% UV initiator (I-2959). Alginate SLG20 and alginate SLM100
hydrogel were formed by mixing the alginate solution (1.4% in 0.9% NaCl) with 20
mM

BaCl2

solution.

All

hydrogel

samples

were

equilibrated

in

sterile

phosphate-buffered saline (PBS) for at least five days with frequent change of PBS to
remove all unreacted small molecule. Before implantation, all samples were shaped
into discs form (D=5 mm) with 1 mm in thickness either using a punch or lancet. The
endotoxin level of implant hydrogels was evaluated using a Limulus Amebocyte
Lysate (LAL) endotoxin assay kit (Cambrex Bioscience) with a detection limit of 0.06
endotoxin units (EU)/ml.
3.2.3 Implantation of hydrogel materials
All animal experiments followed federal guidelines and were approved by the
IACUC at Wayne State University. C57BL/6 mice (male, 20-30g, from Jackson’s Lab)
were anesthetized using isoflurane and received meloxicam analgesia. The surgical
site (dorsal skin) was shaved and prepped with three alternating scrubs of betadine
and alcohol. On prepped animal, a single incision (1.5-2 cm) was made through the
dorsal skin. Bilateral subcutaneous pockets are created by blunt dissection through
the incision for placement of one material sample per pocket. After implantation,
the incisions were closed using wound clips which were removed within two weeks.
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Hydrogel implants were kept in mice for a maximum of 6 months before further
testing.
3.2.4 Histology study: Blood vessel staining and density calculation
At pre-determined time points, mice with implants were euthanized by CO2
asphyxiation. The hydrogel samples together with the surrounding tissue were
excised by cutting around the area with scissors and scalpels. The explanted samples
were then fixed in zinc fixative for 2 days and embedded in paraffin wax. 5 µm
sections were cut and mounted onto slides for histological staining. Blood vessels
were stained brown using rat anti-mouse MECA-32 antibody kit from BD Biosciences
(dilution 1:20; catalog no. 550563), which is an endothelial cell biomarker. Blood
vessel density was calculated by counting the average blood vessel number in 0.2
um2 area with 6 random repeats.
3.2.5 Immunofluorescence staining of macrophage phenotypes
Triple-label immunofluorescence staining was employed to examine phenotypes
of macrophages near to the implant/tissue interface, following the previous
protocol6. Macrophage cells were identified by F4/80 antigen. Phenotype markers
include iNOS, IL-1β, TNF-α, and IL-12 (pro-inflammatory markers), and MMR, Arg1,
IL-10, and TGFβ1 (anti-inflammatory markers). The tissue slides were incubated with
three primary antibodies (rat anti-mouse F4/80 antibody, one pro-inflammatory
antibody (rabbit or goat anti-mouse), and one anti-inflammatory antibody (goat or
rabbit anti-mouse)), followed by incubation with three secondary antibodies labeled
with three different fluorescence tags. Primary antibodies include: rat anti-mouse
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F4/80 antibody (BM8) (dilution 1:50; catalog no. 14-4801-82, eBiosciences), rabbit
anti-mouse iNOS antibody (dilution 1:50; catalog no. ab15323, Abcam), goat
anti-mouse IL-1β antibody (M-20) antibody (dilution 1:50; catalog no. sc-1251, Santa
Cruz Biotechnology), rabbit anti-mouse TNF-α antibody (dilution 1:25; catalog no.
ab9739, Abcam), goat anti-mouse IL-12 antibody (dilution 1:50; catalog no.
NB600-1443, Novus Biologicals), goat anti-mouse MMR antibody (dilution 1:50;
catalog no. AF2535, R&D Systems), rabbit anti-mouse Arg1 antibody (H-52) (dilution
1:50; catalog no. sc-20150, Santa Cruz Biotechnology), goat anti-mouse IL-10
antibody (M-18) (dilution 1:50; catalog no. sc-1783, Santa Cruz Biotechnology),
rabbit anti-mouse TGFβ1 antibody (V) (dilution 1:50; catalog no. sc-146, Santa Cruz
Biotechnology). Secondary antibodies include: donkey anti-rat IgG (dilution 1:200;
catalog no. A-21209, Invitrogen), donkey anti-rabbit IgG (dilution 1:200; catalog no.
A-21206, Invitrogen), and donkey anti-goat IgG (dilution 1:200; catalog no. A-21081,
Invitrogen). For isotype control, rat IgG (dilution 1:80; catalog no. sc-2026, Santa
Cruz Biotechnology), goat IgG (dilution 1:80; catalog no. sc-2028, Santa Cruz
Biotechnology), and rabbit IgG (dilution 1:80; catalog no. sc-2027, Santa Cruz
Biotechnology) were used as primary antibodies. For negative control, no primary
antibodies were used.
3.2.6 FITC-dextran injection and histology study
At pre-determined time points, mice with implants were anesthetized using
isoflurane. 200 µl FITC-dextran/PBS solution (2 mg per 20 g mouse) was injected
through the tail vein. 5 min after injection, mice were euthanized by CO 2
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asphyxiation. The hydrogel samples together with the surrounding tissue were
collected and then fixed in zinc fixative for 2 days and embedded in paraffin wax. 5
µm sections were cut and mounted onto slides, which was directly visualized under a
fluorescent microscope with an excitation wavelength of 488 nm.
3.2.7 Evans Blue injection for accumulation study
At pre-determined time points, mice with implants were anesthetized using
isoflurane. 15 mg Evans Blue in PBS buffer was administrated by i.v. injection for a
mice with 25 g body weight. 5 min after injection, mice were euthanized by CO2
asphyxiation. The hydrogel samples were explanted excluding the surrounding tissue
and immediately exposed to UV (365 nm) for imaging.
3.2.8 Islet isolation
Rat islets were isolated using a method established by Lacy and Kostianovsky 109 as
well as others110-113 and modified by our lab. Briefly, Sprague-Dawley rats (male,
275-300g, from Charles River Lab) were euthanized by CO2 and their bile ducts were
cannulated with an injection of Collagenase P solution. The distended pancreases
were removed and further digested by Collagenase P at 37 oC. Digested pancreases
were quenched with cold PBS, washed, filtered using a 450 µm sieve, and subjected
to Histopaque 1077/PBS gradient purification. Islet layer was taken and further
purified by hand-picking islets. Resulting islets were counted and cultured in RPMI
1640 media with 10% fetal bovine serum and 1% penicillin/streptomycin at 37 °C in
humidified air containing 5% CO2.
3.2.9 Islet encapsulation and transplantation
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To encapsulate a large number of islets by PCBAA hydrogel for therapeutic
purpose, the isolated rat islets will be first encapsulated by 1.4% Alginate SLG20 after
mixing the islet/alginate preparation with 20 mM BaCl2 solution, and then be shaped
into disks of 3 mm in diameter and 1 mm in thickness. The islet containing small
disks will be placed between two glass slides separated by Teflon spacers (2 mm in
thickness), suspended in a pre-gel solution (containing zwitterionic CBAA monomer,
MBAA crosslinker, and photoinitiator I2959 in PBS), and chemically crosslinked at
365 nm UV. The resulting hydrogel sheets will be removed and equilibrated in cell
culture medium, and tailored into macro disks using a 5-mm biopsy punch for
transplantation (islets encapsulated within the 5 mm PCBAA disk). SLG20/islet and
SLM100/islet controls were obtained by mixing the islet/alginate preparation (1.4%
alginate concentration) with 20 mM BaCl2 solution, and then be shaped into disks of
5 mm in diameter and 2 mm in thickness.
C57BL/6 mice (male, 20-30g) received a daily i.p. injection of 5 mg/ml streptozocin
(STZ) at 50 mg/kg for 5 consecutive days. STZ-mice were placed on a non-fasted
regular diet. 17 days after the first injection, weight and blood glucose were
measured to confirm diabetic status. Only mice whose non-fasted blood glucose
levels were above 300 mg/dL for two consecutive days were considered diabetic and
underwent transplantation. PCBAA/islet, SLG20/islet, and SLM100/islet disks were
s.c. implanted in diabetic mice at day 0 following the implantation procedure
described above. After implantation, the animals’ blood was sampled three times a
week before the endpoint. Blood drop was collected from the tail using a lancet and
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tested using a commercial glucometer (Clarity One, Clarity Diagnostic Test Group).
Typically, the mice blood glucose was observed to drop one or two days after the
implantation. Mice with a non-fasted blood glucose below 200 mg/dL were
considered normoglycemic. Transplanted mice maintaining normoglycemia (i.e.,
received PCBAA/islet) and those returning to hyperglycemic state (i.e., received
SLG20/islet and SLM100/islet) were subject to explantation. Explanted islets were
stained by Live and Dead staining kit (Life technology) to visualize the survival of
islets.
3.2.10 Glucose-stimulated insulin secretion (GSIS) assay
Explanted hydrogels with islets encapsulated were pre-incubated for 1 h in
FBS-free RPMI 1640 containing 2.8 mmol glucose in a 6-well plate at 37°C incubator
in 5% CO2. In the following 3 hours, RPMI 1640 medium with 2.8 mmol glucose, 28
mmol glucose, and 2.8 mmol glucose was added consecutively, 1 h respectively.
After each incubation, the media was collected and stored at -20 °C for future insulin
concentration determination. The rat insulin concentration in the culture media was
evaluated using Mercodia ultrasensitive rat insulin kit (Uppsala, Sweden) with three
repeats for every group.
3.2.11 Statistical Analysis
n = 6 was used for mice per time point or per treatment group unless specified
otherwise. The sample size was selected according to previous reports. All tested
mice were included in analyses except for ones with unforeseen sickness or
morbidity. Animal cohorts where randomly selected and investigators were not blind

34
to performed experiments. Representative images illustrated are based on n = 3
mice per treatment group unless specified otherwise. Most data were normally
distributed and similar variance was determined for groups that are compared.
Analysis includes unpaired two-tailed t-test and one-way analysis of variance
(ANOVA) with Bonferroni multiple-comparison correction. For data not following
normal distribution, non-parametric Mann-Whitney test was used. *: P < 0.01, **: P
< 0.001, ***: P < 0.0001 and n.s: no significant difference. For all statistical analyses,
significance was accepted at the 95% confidence level.
3.3 Results
3.3.1 Implanted zwitterionic hydrogel healed like a natural wound, and promoted
vascularization to the same density level as normal tissue.
The zwitterionic hydrogel was made from zwitterionic carboxybetaine acrylamide
(CBAA) monomer (synthesized as previously documented108) and a widely used
N,N-methylenebis(acrylamide) (MBAA) crosslinker through ultraviolet (UV) induced
crosslinking (structure in Figure 3-1(a)). The resulting hydrogel was equilibrated in
phosphate buffered saline (PBS) and punched into disks of 5 mm in diameter and 1
mm in thickness. Zwitterionic hydrogel disks along with other hydrogel controls of
the same dimension were then subcutaneously (s.c.) implanted on normal healthy
mice. One month after implantation, hydrogel samples with surrounding tissue were
collected for histology study. An incised subcutaneous wound healed for one month
(no hydrogel implanted) and a normal healthy subcutaneous tissue were also
collected for comparison. By staining the tissue slides with an antibody binding to
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MECA-32 on endothelial cells, blood vessels can be visualized (shown by brown color)
and their density can be calculated.
The major finding was that the zwitterionic hydrogel implant promoted blood
vessel formation which was similar to healthy tissues in vessel density. It was clearly
showed that new blood vessels formed near to the zwitterionic PCBAA hydrogel
surface (Figure 3-1(b)) with a vessel density comparable to physiologically healed
and healthy tissues (no significant difference at p > 0.58; Figure 3-1(c)). On the
contrary, the Alginate SLG20 hydrogel, PEGDA 10K hydrogel and PHEMA hydrogel
(made

from

2-hydroxyethyl

methacrylate

(HEMA))

had

much

fewer

neovascularization in the surrounding area; this is significantly different from PCBAA
hydrogel (p < 0.0001). It was worth mentioning that these control materials (alginate,
PEG, and PHEMA) have been intensively studied for implantation purposes, such as
for tissue engineering114-115, device coating116-117, and cell therapies118-126. It was
further observed that such high level of blood vessel density induced by the
zwitterionic hydrogel can last at least 6 month in the transplantation study (no
significant change over time at p > 0.31; Figure 3-1(d); representative histological
images shown in Figure 3-2).
We did not observe a sign for uncontrolled blood vessel formation in the
surrounding area of the zwitterionic hydrogel, indicating that the hydrogel was not
like a tumor that induces uncontrolled neovascularization. A melanoma tumor was
developed by s.c. injection of 1x105 murine B16F10 cells s.c. to the back on health
mice on the left flank. Two weeks later, tumor tissue was explanted for similar
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histological analysis using anti-MECA-32 blood vessel staining. It was found that the
tumor blood vessels showed structurally disordered, abnormal morphology (in
agreement with the literature127) and their density was estimated to be at least
three times of that of normal tissue and the tissue interfaced with PCBAA hydrogel
(Figure 3-3).
3.3.2 The newly formed blood vessels were perfused, and approached the
implanted zwitterionic hydrogel surface as close as below 20 µm away.
Based on the finding that the implanted zwitterionic PCBAA hydrogel induced
vascularization to a density level comparable to that of a naturally healed wound and
normal tissue level, it is essential to know whether these newly formed blood vessels
are functional and perfused with circulating blood. To address this question, we
injected FITC-dextran solution through the tail vein to healthy mice previously
received the s.c. implant of different hydrogel materials for one month. 300 seconds
following the injection, implanted hydrogel samples with surrounding tissue were
collected for tissue sectioning (Figure 3-4(a)). Using a fluorescent microscope, it was
discovered that the newly formed vessels were highly perfused with function, which
was proved by the green dye in the lumen of the vessels in the surrounding of PCBAA
hydrogel. For alginate and PEGDA hydrogel surface tissue, however, no significant
amount of green-labeled blood vessel can be observed (Figure 3-4(b)). The density of
neovascularization could also be calculated based on the green-labeled tissue slides
(Figure 3-5), and was found to be comparable to MECA-32 staining results (Figure
3-1(c)).
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It is particularly worth noting that the newly formed blood vessels approached the
zwitterionic hydrogel surface as close as possible. We created a penetrating hole (1
mm in diameter) in the center of the hydrogel disk, or an inter-space between two
identical disks (Figure 3-4(d)), and s.c. implanted them for one month. Mice then
received a tail-vein injection of FITC-dextran, and 5 min later hydrogels together with
surrounding tissues were histologically analyzed. It was obvious that new blood
vessels grew into the holes and narrow space between zwitterionic hydrogel
surfaces after one-month implantation (Figure 3-4(c)), and also maintained their
presence after two-month implantation (Figure 3-6). We further measured how
close these new functional vessels were to the zwitterionic surface in the cases of
hydrogel disks, holes, and interspaces, and found that the nearest blood vessels
were typically within a perpendicular distance of 20 µm from the gel surface (Figure
3-4(e)). Considering a typical animal cell size of 10-20 µm in diameter, the
zwitterionic implant surface is expected to be highly accessible by the blood with
only one or a few cell layers in between.
3.3.3 Implanted zwitterionic hydrogel was highly accessible by circulating blood for
up to five months.
The function or tissue and organ were supported by the blood that transports
oxygen, nutrient and metabolic waste128. It will be ideal that an implantable device
can achieve a similar level of blood accessibility as regular tissue to sustain efficient
transport and communication between the device and its environment. Based on the
finding that abundant of perfused blood vessels were grown and approached the
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zwitterionic gel surface down to 20 µm range, we expect the hydrogel can be easily
accessible by circulated blood components. This was evaluated by quantifying the
freshly injected dye molecules that circulated through blood and accumulated to the
implanted hydrogels. Healthy mice received s.c. implantation of hydrogel samples
for up to 5 months, and was then injected with Evans Blue through tail vein. Evans
blue was a nontoxic dye that was widely applied as a contrasting agent to improve
resolution of small veins129. 5 min after injection, mice were sacrificed and hydrogel
samples were immediately explanted, visualized under UV (Figure 3-7(a)), and
quantified for dye accumulation (Figure 3-7(b)). It was found that all tested hydrogel
samples implanted for 1 day were not able to effectively recruit the dye due to the
destruction of nearby blood vessels during the implantation surgery. For zwitterionic
PCBAA disk, the dye accumulation was found to be significant at 2 weeks after
implantation (Figure 3-8), and reached its maximum during the 2 to 5 months
post-implantation window. By contrast, non-zwitterionic controls, PEGDA 10K and
Alginate hydrogels, exhibited negligible fluorescent intensity during the entire study
period (p < 0.0001). This result indicates that the implanted zwitterionic hydrogel is
able to maintain superior blood accessibility for a long term, which has rarely been
obtained by known implanted synthetic materials.
3.3.4 zwitterionic hydrogel enabled the survival and function of encapsulated
xenograft islets and improved therapeutic outcome at subcutaneous site
To highlight the implications of our findings, we studied whether the unique and
desirable feature of implanted zwitterionic hydrogel, i.e., normal-tissue like blood
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vessel density and superior blood accessibility, can improve the performance of an
implantable device. Particularly we employed zwitterionic hydrogel for islets of
Langerhans (islets) encapsulation and subsequent xenograft transplantation.
Conventional biomaterials such as alginate and PEG have been widely used to
encapsulate/immuno-isolate the islets, but their therapeutic potential was
jeopardized since nutrients and oxygen can hardly reach the implanted device to
sustain the cell viability130-131. When islets are transplanted at s.c. site, their viability
is even worse since s.c. site is generally less blood accessible comparing with other
locations, such as intraperitoneal (i.p.) site132. It has been reported that alginate
based materials sustained islet survival at the i.p. site but failed at the s.c. site133, and
the i.p. location was mostly used in evaluating performance of islet encapsulating
devices134-135. Regarding the challenge above, we expect that islets transplantation
outcome at the convenient s.c. site can be significantly improved through
zwitterionic hydrogel encapsulation.
Our study involved two phases. At phase one, PCBAA and control hydrogel
materials (Alginate SLG20 and PEGDA 10K) were used to encapsulate a few rat islets
and the hydrogel/islet constructs were s.c. implanted in healthy mice. Each
encapsulating construct included 3-6 islets in order to tract and identify the size,
location, and survival condition of each islet after explantation. It was found that
islets encapsulated by zwitterionic PCBAA hydrogel were healthy under a microscope
after one-month implantation, however, islets in the Alginate and PEGDA hydrogels
were either dead or hard to be visualized (Figure 3-9). The explanted hydrogel/islet
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constructs were further challenged continuously by three glucose concentration
levels (2.8, 16.7, 2.8 mmol; each for 1 h) to evaluate the insulin producing capability
of the transplanted islets in a glucose challenge methods (Figure 3-9). It was showed
that islets encapsulated in PCBAA hydrogel sustained their glucose response
capability after 30 days in mice (no significant difference, p > 0.53), but control
materials failed to render islets normal GSIS function (p < 0.0001).
At phase two study, we encapsulated larger amount of rat islets and examined
whether zwitterionic hydrogel encapsulation outperformed the conventional
alginate SLG20 encapsulation in achieving insulin independence of diabetic mice. We
chose 500 islet equivalents (IEq) from rat, and transplanted the devices to s.c. site of
streptozotocin (STZ)-induced C57BL/6 diabetic mice. Notably, 500 IEq rat islets
encapsulated by Alginate SLG20 have been reported to achieve at least ~20 days
insulin independence at i.p. site. Here we found that Alginate SLG20 hydrogel/islet
started to fail at ~10 days after s.c. transplantation in lowering blood glucose of
diabetic mice (therapeutic level is 200 mg/ml) (Figure 3-10(a)). Meanwhile,
zwitterionic PCBAA gel/islet was found to sustain the diabetes reversal during the
entire 80 days of implantation period (Figure 3-10(b)). When PCBAA hydrogel/islet
was retrieved on day 83, the blood glucose immediately went back to the
pre-treatment level. Live and dead staining (green-fluorescent calcein-AM (live)/
red-fluorescent ethidium homodimer-1 (dead)) indicated that the explanted islets
protected by PCBAA gel maintained their healthy condition (Figure 3-10(a)). The
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supreme capability to sustain islet survival and glucose response was due to the
great blood vessel formation and tissue integration of PCBAA hydrogel.
3.3.5 Implanted zwitterionic hydrogel had an unusual anti-inflammatory effect on
local surrounding tissues.
Among conventional biomaterials for implantable applications, high mannuronate
(M) alginate has been identified to be able to promote blood vessel formation to
certain extent, and has been used to encapsulate islets and demonstrated control of
fasted diabetic non-human primate blood glucose for half a year136-137. However, the
application of high-M alginate hydrogel was hindered due to the pro-inflammatory
reaction produced by the material, with monocytes that produced high level of IL-1
TNF-α and IL-6 which endangered the long-term survival of the islet138-139. Here we
evaluated the potential inflammatory response of zwitterionic hydrogel materials
together with control materials including high M alginate (Alginate SLM100, low
endotoxin, from FMC Biopolymer). One month after s.c. implantation of these
material disks in healthy mice, the materials with surrounding tissues were
explanted and subjected to immunofluorescence histological study. Macrophages in
the vicinity of the implant and their expressed pro-inflammatory (TNF-α, IL-1β, IL-12,
iNOs) and anti-inflammatory cytokines (IL-10, TGF-β1, Arg-1, MMR) were triple
labeled (Figure 3-11(a)). Zwitterionic PCBAA stimulate significantly less inflammatory
cytokines, particularly compared with Alginate SLM100, PEGDA 10K, and PHEMA
(p<0.0001), and drastically more anti-inflammatory factors, i.e., IL-10, compared
with all tested control biomaterials (p<0.0001) (Figure 3-11(b)). With superior blood
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accessibility plus the unusual anti-inflammatory capability, zwitterionic PCBAA
hydrogel is expected to outperform most current biomaterials, including the highly
promising high M alginate, in boosting the outcome of current implantable devices.
In our islet encapsulation and s.c. transplantation test, we indeed observed that
Alginate SLM100/ islet implant failed to control blood glucose starting at day ~10,
while zwitterionic PCBAA/islet continuously reversing diabetes through the entire 80
days of implantation (Figure 3-12).
3.4 Discussion
Our body evolved a vasculature systems with high density of blood vessels to
enable sufficient exchange of oxygen, nutrition and metabolic waste of every single
cell. An implantable device, ideally, requires a similar level of blood accessibility to
sustain long-term therapeutic or monitoring function. However, most biomaterials
could not evade foreign body attack and were unable to support blood vessel
formation, no matter they are polymers, metals, or ceramics140-143. Our study for the
first time showed that (1) zwitterionic hydrogel material supports the growth of new
blood vessels to the same density level as naturally healed wound and healthy tissue,
and maintains such natural density of vasculature for a long term. It is particularly
noted that there is no sign of uncontrolled angiogenesis near to the zwitterionic
hydrogel surface; this, however, is frequently observed with tumor vasculature, and
when growth factors were overly delivered at the implantation site 144-145. We further
found that (2) the newly formed vessels were highly perfused with function, which
was proved by the green dye in the lumen of the vessels in the surrounding of PCBAA
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hydrogel, and were discovered to stay very close to the PCBAA hydrogel surface and
grow into the holes or the narrow space between two PCBAA hydrogels. By
measuring how close these new functional vessels were to the zwitterionic surface in
the cases of hydrogel disks, holes, and interspaces, it was found that the nearest
blood vessels were typically within a perpendicular distance of 20 μm from the
hydrogel surface. This indicated that the zwitterionic implants could be potentially
highly accessible by the blood with one or a few cell layers in between. We further
verified that (3) zwitterionic hydrogel implants are highly blood accessible, as
indicated by the efficient accumulation of Evans blue dye on the hydrogel device,
even after 5 months of implantation. It is worth noting that most of the current
studies on blood vasculature around biomaterials focused mostly on blood vessel
morphologies. Our work provided insights on the function of the newly formed
vasculature and the blood accessibility of the implants. With natural tissue-like
vasculature and superior blood accessibility, the zwitterionic hydrogel is expected to
be a promising platform to improve long-term implantable device outcome (such as
being the coating or surface materials for implantable devices).
Our implantation study was exclusively performed on the subcutaneous (s.c.) site
for two reasons. First, this location is ideal for many commonly found implantable
devices such as vascular access devices, contraceptive devices, blood glucose sensor,
cell delivery devices, cardioverter defibrillator: S.c. site is the most welcomed
implantation site for the patience. The surgery could be easily performed in a local
clinic without general anesthesia. If there is some malfunction happen to the device,
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it will be easily retrieved and replaced to elongate the therapeutic function period.
Second, s.c. site is known for poor vascularization, and is known to have less blood
accessibility comparing to intraperitoneal (i.p.) or other sites. We showed
remarkable neovascularization promotion and blood accessibility at this challenging
site with zwitterionic hydrogel implants. This effectively addresses the current
challenge preventing s.c. implant from achieving long-term device outcome, and also
implies that zwitterionic hydrogel implants can perform as efficiently at other
implantation sites.
To highlight the capability of the zwitterionic hydrogel in improving implantable
device outcome, we studied zwitterionic hydrogel as a novel material for islet
encapsulation and transplantation. Islet Encapsulation by biomaterials is a potential
solution to treat Type 1 Diabetes with insulin independence free of
immunosuppressant146-148. Encapsulated islets will be protected by the polymers
hydrogels from the attack of the body immune system and are shown to long term
manage blood glucose. Nevertheless, there was few clinically relevant product of
islet encapsulation even with over decades of research149. The crucial point in the
successful islet transplantation is to sustain function and survival of the transplanted
islets for a long term. Current biomaterials including hollow fiber, natural polymers
such as agarose and alginate, and synthetic PEG have been extensively used as islet
encapsulation materials150-152. These materials, however, resulted in poor blood
accessibility after transplantation, which hindered the survival of islets because the
blood/oxygen exchange was cut off. This hinders glucose/insulin transport and
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prevents the implant from achieving desired long-term therapeutic function153-155.
Here we observed that with superior blood accessibility, islets encapsulated by
zwitterionic hydrogel achieved greatly improved therapeutic outcomes. In the s.c.
site, zwitterionic PCBAA hydrogel/islet was able to correct diabetes during the entire
80 days of implantation period, while both Alginate SLG20 gel/islet and SLM100
gel/islet, two state-of-the-art technology, failed to lower blood glucose starting at
less than 10 days (Figure 3-10, Figure 3-12).
It is important to compare the zwitterionic PCBAA with Alginate SLM100 (high
mannuronate (M)) and SLG20 (high guluronate (G)), two of the most popular
alginate materials currently used for islet encapsulation, from both blood vessel
promotion and anti-inflammatory standpoints. We consider inflammatory response
in this comparison because most islet encapsulating materials are known for
stimulating the production of cytotoxic cytokines upon implantation that penetrated
to the encapsulated islets and cause islet death. Alginate SLM100 as s.c. implant with
islet encapsulated has demonstrated the management of fasted blood glucose for
half a year in diabetic primate studies. Our results show that SLM100 after 1-month
s.c. implantation promoted new blood vessel growth to a density of 9.6±1.8 blood
vessels per 0.2 mm2, but is still far below the 22.7±3.4 blood vessels per 0.2 mm 2 for
PCBAA that matched the normal tissue level (Figure 3-13). In addition, SLM100 (high
M) was found to stimulate severe inflammatory response than SLG20156 (high G)
(Figure 3-11), and high level of IL-6, IL-1 and TNF-α greatly endangered the long-term
survival of transplanted islets. SLG20, by contrast, showed fewer pro-inflammatory
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reaction compared with high-M alginates (Figure 3-11, well-consistent with the
literature), and have been alternatively used for islet encapsulation. But SLG20 is
even worse in promoting blood vessel growth (3.3±0.3 blood vessels per 0.2 mm2,
Figure 3-1(c)). The advantage of zwitterionic PCBAA is obvious: it shows the
strongest neovascularization promotion (as good as natural body system), the least
inflammatory cytokine secretion, and the highest anti-inflammatory response. By
overcoming both the blood vessel and inflammation challenges, zwitterionic PCBAA
encapsulation technology has great potential to outperform the state-of-the-art islet
encapsulation strategies in supporting long-term viability and function of
transplanted islets.
In summary, we report the first synthetic material ever known, namely
zwitterionic hydrogel, promoting functional neovascularization as good as natural
body system. This finding has a promising impact on current implantable devices in
improving the device outcome. To highlight this implication, zwitterionic hydrogel
was used to encapsulate islet cells for T1D treatment, with therapeutic outcome
remarkably outperforming the state-of-the-art technologies.
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Figure 3-1 (a) Molecular structure of carboxybetaine acrylamide (CBAA) monomer
and MBAA crosslinker which that used for making the PCBAA hydrogel. (b)
represented histology images on blood vessel formation of hydrogel samples,
healthy tissue and self-heal incision after one month transplantation. (c) The
calculated density of blood vessels of all samples in (b). (d) Calculated blood vessel
density for Long-term PCBAA hydrogel implantation in mice for up to half a year. All
data are presented as mean of biological replicates (n=6) ± standard deviation.
Statistical analysis: one-way ANOVA with Bonferroni multi-comparison. ***: p <
0.0001; n.s.: no significant difference.
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Figure 3-2 Representative images of MECA-32 antibody staining of PCBAA
hydrogel/tissue interface after 2, 3, 4, and 6 months of implantation. Scale bar = 50
μm.

Figure 3-3 (a) A represented image of MECA-32 antibody staining of B16F10
melanoma tumor tissue. Scale bar = 50 μm. (b) Calculated blood vessel density of
PCBAA hydrogel/tissue interface, normal tissue and tumor tissue, based on MECA-32
staining results. All data are presented as mean of biological replicates (n=6) ±
standard deviation. Statistical analysis: one-way ANOVA with Bonferroni
multi-comparison. ***: p < 0.0001; n.s.: no significant difference (p > 0.62).
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Figure 3-4 (a) Illustration of green dye injection experiment. The mice with
implanted samples receive tail vein injection of FITC-dextran in PBS solution. The
samples and surrounding tissue were retrieved for imaging. (b) Represented images
of FITC-dextran stained blood vessels for all hydrogel samples under fluorescence
microscope. Scale bar = 50 μm. (c) images showing blood vessels grown into the hole
in the center of a hydrogel disk and narrow space between two hydrogel disks. Scale
bar = 400 μm. (d) Schematic representation of the two approaches in (c). (e) Blood
vessels near to PCBAA hydrogel implants were perfused with green FITC-dextran.
Gel/tissue interface was labeled by white dash lines. 20 μm away from the interface
was depicted by red dash lines. Scale bar = 50 μm.
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Figure 3-5 Blood vessel density for PCBAA, Alginate SLG20 and PEGDA 10K
hydrogel/tissue interface, calculated from FITC-Dextran injection experiment. Data
were presented as mean of biological replicates (n=3) ± standard deviation.
Statistical analysis: one-way ANOVA with Bonferroni multi-comparison. ***: p <
0.0001

Figure 3-6 Fluorescent image on tissues interfaced with PCBAA hydrogel disk
containing a premade hole. The hydrogel disk was implanted for 2 months followed
by FITC-Dextran perfusion on blood vessels. Scale bar = 400 μm

51

Figure 3-7 (a) dye accumulation of all explanted hydrogel samples (after different
time points) under UV lamp after receiving i.v. injection of Evans Blue dye in PBS. (b)
Fluorescent intensity quantification from (a). All data are presented as mean of
biological replicates ± standard deviation (n=4, (n=3 for PCBAA at 5 months)).
Statistical analysis: one-way ANOVA with Bonferroni multi-comparison. ***: p <
0.0001.
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Figure 3-8 Evans Blue dye accumulation on Alginate SLG20, PEGDA 10K and PCBAA
hydrogels that have been implanted for 15 days.

Figure 3-9. The first line exhibited the islets morphology in different materials after
30 days’ implantation in normal healthy mice. The second line showed the
corresponding glucose response capability of islets in different materials after 30
days’ implantation. All data are presented as mean of biological replicates (n=6) ±
standard deviation. Statistical analysis: one-way ANOVA with Bonferroni
multi-comparison. ***: p < 0.0001; n.s.: no significant difference at p > 0.53.
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Figure 3-10 (a) Therapeutic curve of PCBAA hydrogel and Alginate SLG20 hydrogel
devices with 500 IEq rat islets encapsulated. Live (green) and Dead (red) staining was
performed at the end point as indicated. (b) The fraction of cured diabetic mice after
being transplanted (non-fasted blood glucose level < 200 mg/dl). All data are
presented as mean of animal replicates (n=6) ± standard deviation. Statistical
analysis: non-parametric Mann-Whitney test. **: p < 0.001.
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Figure 3-11 (a) Macrophages in the vicinity of different material implants (within
~100 μm from the tissue/hydrogel interface) were analyzed after 1-month
implantation. Representative immunofluorescence histological images were
obtained through triple staining with the indicated markers. (b) Percentage of
macrophages expressing pro-inflammatory (interleukin 10 (IL-10), transforming
growth factor beta 1 (TGF-β1), arginase-1 (Arg-1) and macrophage mannose
receptor (MMR)) and anti-inflammatory (tumor necrosis factor alpha (TNF- α),
interleukin 1 beta (IL-1 β), interleukin 12 (IL-12) and Inducible nitric oxide synthase
(iNOs)) biomarkers. All data were showed as mean of biological replicates (n=10) ±
SEM. Statistical analysis: one-way ANOVA with Bonferroni multi-comparison. *: p <
0.01; **: p < 0.001; ***: p < 0.0001; n.s.: no significant difference at P > 0.05.
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Figure 3-12 (a) Therapeutic curve of PCBAA hydrogel, alginate SLG20 gel and alginate
SLM100 gel devices with 500 IEq rat islets encapsulated. (b) The fraction of cured
diabetic mice after being transplanted (non-fasted blood glucose level < 200 mg/dl).
All data were showed as mean of animal replicates (n=6; for SLM100, n=4) ±
standard deviation. Statistical analysis: non-parametric Mann-Whitney test. **: p <
0.001.
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Figure 3-13 (a) Representative image of MECA-32 antibody staining of Alginate
SLM100 hydrogel/tissue interface. Scale bar = 50 μm. (b) Calculated blood vessel
density of PCBAA hydrogel/tissue interface and alginate SLM hydrogel/tissue
interface, based on MECA-32 staining results. Data were showed as mean of
biological replicates (n=3) ± standard deviation. Statistical analysis: unpaired,
two-tailed t-test. **: p < 0.001
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CHAPTER 4. A MACRO-CROSSLINKER FOR DURABLE ANTI-FOULING COATING
4.1 Introduction
Zwitterionic polymer coatings were effective to solve Biofouling problem that
causes implantable device failure and unwanted microorganism attachment.
However, zwitterionic polymer coating is usually fragile with only short-term function
since these super-hydrophilic polymers tends to dissolve in water. In this chapter, we
described and synthesized a novel zwitterionic macro-crosslinker to overcome the
vulnerability of zwitterionic coating. The macro-crosslinker coating was highly
crosslinked over the whole surface with much greater thickness than common
polymer brush coating and stayed in presence on polyurethane (PU) surface to
maintain function even after long term treatment in flowing phosphate buffered
saline (PBS). The macro-crosslinker coating enabled the application of zwitterionic
polymer in durable anti-biofouling coating for long term function.
For many applications involving surface exposure to biomolecule and
microorganism, biofouling is a serious problem that causes implantable device
failure157-158 and unwanted microorganism attachment159-160. Recently, surface
modification with non-fouling polymer has been utilized to overcome the biofouling
problem161-162. Encouraging results had been obtained in various applications on
different traditional substrates such as anti-thrombosis polyurethane catheters and
coatings on metal ship hull to resist marine fouling163 by using non-fouling
zwitterionic polymers. Zwitterionic polymer coatings are super-hydrophilic and
attract a dense layer of water molecule to resist non-specific protein binding and
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bacteria adhesion164. Many methods have been involved in fabricating zwitterionic
coatings165. Nevertheless, the resulting zwitterionic polymer coatings are typically
unstable with only short-term function, regardless of how they are immobilized on
the surface166. Unlike hydrophobic polymer coatings, super-hydrophilic polymer
coatings drastically tend to dissolve into water environment. This leads to gradual
exposure of the coated surface over time167, and hinders the use of zwitterionic
coating in applications that require long term durability46. Despite significant efforts
in this field168, it remains a challenge to fabricate durable non-fouling coating using
super-hydrophilic zwitterionic polymers.
In this work, we synthesized zwitterionic macro-crosslinker to overcome the
vulnerability and challenge in developing durable anti-fouling coatings. Double bonds
were introduced to high molecular weight (Mw) zwitterionic polymer backbone,
which was then crosslinked on polyurethane substrate by graft-from method.
Different from single polymer chain which was easily torn away from the surface, the
macro-crosslinker coating was highly crosslinked over the whole surface with
significantly increased thickness and remained on polyurethane (PU) surface to
sustain non-fouling function even after long term shearing in flowing phosphate
buffered saline (PBS). Synthesis of the zwitterionic macro-crosslinker was verified by
Nuclear Magnetic Resonance (NMR) and coating thickness was characterized by
surface ellipsometry and scanning electron microscope (SEM) visualization. Contact
angle, protein absorption and bacteria adhesion were utilized to examine the
function of the coating after different durability challenges. Results indicated the

59
macro-crosslinker coating was much more durable than common brush polymer
coating and conventional small molecule crosslinking strategy, indicating its potential
for durable (or long-term) anti-fouling applications.
4.2 Materials and methods
4.2.1 Materials
2-Aminoethyl methacrylate hydro-chloride (NH2-MA monomer, 90%), Tert-Butyl
bromoacetate

(98%),

2-(Dimethylamino)

ethyl

mathacrylate

(DMA

98%),

N,N-Methylenebis(acrylamide) (MBAA, 99%), Anhydrous DMF, Anhydrous Acetone
(99.99%) and Anhydrous methanol were purchased from Sigma-Aldrich, St. Louis,
MO. Triethylamine (TEA, 99%), trifluoroacetic acid (TFA, 99.9%) and Ethyl Ether
anhydrous (99.9%) were obtained from Fisher Chemical. Co. Deuterium Oxide (D 2O
99.9%) and Dimethyl sulfoxide-D6 (D-DMSO, 99.9%) were obtained from Cambridge
Isotope Laboratories, Inc. USA.
4.2.2 Synthesis of PCBMA-tBu monomer
The

synthesis

procedure

was

as

reported

previously4.

Briefly

5

g

2-Dimethylamino-ethyl methacrylate and 8.68 g tert-butyl bromoacetate were
reacted in 20 ml acetonitrile for 24 h at 50 oC under N2 protection. Upon addition of
250 ml ethyl ether to the reaction mixture, the white crystals were isolated and dried.
The resulting CBMA-tBu monomers were immediately stored in a desiccator at -20 oC
(yield 96%)
4.2.3 Synthesis of PCBMA macro-crosslinker
The

polymerization

solvent

was

prepared

by

dissolving

5

mg
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2-Hydroxy-4-(2-hydroxyethoxy)-2-methylpropiophenone (photo-initiator, I-2959) in
anhydrous DMF. The CBMA-tBu ester monomer was first copolymerized with
2-Aminoethyl methacrylate hydro-chloride (NH2MA monomer) at different molar
ratio (10:1, 30:1 and 50:1) in the polymerization solvent (35% by weight) under UV
for 10 min and the resulting polymer A was precipitated in anhydrous acetone.
Unreacted monomer was washed away by re-dissolving the product in DMF and
precipitated in acetone for additional two times (polymer yield: 56%). The purified
copolymer A was then reacted with acryloyl chloride (3 times of the amount of NH 2
function group) in presence of triethylamine in anhydrous DMF (10% by weight) for 5
h at room temperature followed by precipitation in anhydrous ethyl ether and
vacuum dry (polymer B, yield: 87%). Lastly, copolymer B was stirred in trifluoroacetic
acid (20% by weight) to remove tBul ester protection and neutralized using
triethylamine (TEA) to pH=7 in anhydrous methanol on ice bath. The obtained
zwitterionic macro-crosslinker C was precipitated in ethyl ether and dried in vacuum
(macro-crosslinker C yield: 91%; overall yield: 44%).
4.2.4 Characterization
The molecular weight of the macro-crosslinker and surface initiated polymer
(obtained by ultrasonic treatment after coating) were determined by gel permeation
chromatography (GPC) on a Waters Alliance 2695 Separations Module equipped with
a Waters Ultrahydrogel Linear column and a Waters 2414 reflex detector. The mobile
phase was PBS buffer solution at a flow rate of 0.7 ml/min at 35 oC. Poly(ethylene
oxide) from Polymer Laboratories were used as standards. The synthesized products
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were examine using a Varian Mercury-400 MHz NMR. In Figure 2 of the main text,
the product A and B were dissolved in D-DMSO and product C was dissolved in D2O.
The coating thickness was characterized by surface ellisometry and averaged from
three measurements at different surface site (α-SETM, J.A. Woollam Co., Inc.).
4.2.5 Protein absorption
To measure the fibrinogen (Fg, Sigma-Aldrich) adsorption on PCBMA
macrocrosslinker coating, coated surface (either by PCBMA brush or PCBMA
macrocrosslinker) and bare PU surface were incubated with 1mg/ml Fg in a well plate
for 10 minutes at room temperature, followed by 5 washes with PBS buffer. Samples
were then incubated with 1 mg/ml bovine serum albumin solution for 10 minutes at
room temperature with 5 times wash again with PBS buffer. The tested surface were
then removed from the fifth PBS wash and transferred to new wells. They were next
incubated with a 1:200-dilution of horseradish peroxidase (HRP)-conjugated
anti-fibrinogen in PBS for 10 minutes, followed by another 5 washes with the same
buffer. After the fifth wash, the tested surfaces were transfer to new wells and
SIGMAFAST OPD was added to each well at 30-second intervals. The surfaces were
incubated in the OPD solution for 30 minutes away from light. The supernatant was
removed from each test well, transferred to a cuvette, and its absorbance at 490 nm
was measured. All samples were measured in triplicate.
4.2.6 Bacteria adhesion and SEM image
After bacteria adhesion on PU, the surface will be immersed in the fix solution of
2.5% gluaraldehyde, 2% paraformaldehyde in 0.1 M sodium phosphate buffer. The
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surface was then dehydrate in a gradient ethanol series and dried in vacuum. Before
imaging, the surface sample was coated with nano-gold using a SEEVac Conductive IV
sputter coater. The bacteria were imaged using a JSM - 6510LV SEM at 5 um
magnification and bacteria adhesion density was calculated by counting the bacteria
number per 900 um2.
4.3 Results and discussions
The synthesis of zwitterionic macro-crosslinker, based on polycarboxy betaine
methacrylate (PCBMA), involves 3 steps of reaction and each step was monitored by
1H-NMR

(Figure 4-1). The CBMA-tBul ester monomer was first copolymerized with

2-aminoethyl methacrylate hydro-chloride (NH2MA monomer) at different molar
ratio (m:n=10:1, 30:1 and 50:1) in anhydrous dimethylformamide (DMF) using
random free radical polymerization and the resulting polymer A was precipitated in
anhydrous acetone. Unreacted monomer was washed away by re-dissolving the
product in DMF and precipitated in acetone for additional two times. NMR spectrum
for polymer A showed no peak between 5-6 ppm, indicating the complete removal of
both unreacted CBMA-tBu and NH2MA monomers. An emerging peak (b at 7 ppm)
implied successful incorporation of NH2MA unit into the PCBMA-tBu ester polymer
backbone. The purified copolymer A was then reacted with acryloyl chloride in
presence of triethylamine in anhydrous DMF followed by precipitation in anhydrous
ethyl ether and vacuum dry. The obtained copolymer B had its NMR peak b
completely replaced by peak c (5-6 ppm, for acryloyl chloride) with an undetectable
peak d (7.9 ppm for -NH-); this indicated that the NH2 function groups from NH2MA
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were completely reacted with acryloyl chloride. Lastly, copolymer B was treated by
trifluoroacetic acid (TFA) to remove tBu ester protection and neutralized using
triethylamine (TEA) to pH=7 in anhydrous methanol on ice bath. The obtained
zwitterionic macro-crosslinker C was precipitated in ethyl ether and dried in vacuum
(overall yield: 44%). Complete removal of tBu ester groups was confirmed by the
disappearance of peak a (1.2 ppm) for tBu ester shown in copolymer A and B (spectra
for different double bond ratio see Figure 4-2). Free radical polymerization was
chosen here since there was no any toxic catalyst involving and small molecule could
be easily removed, which was crucial for potential in vivo application such as coatings
for catheters.
The coating on hydrophobic PU substrate was produced by a surface graft-from
redox polymerization method which was reported previously169. We chose graft-from
method because it was able to induce densely distributed polymer chain that was
proved to effectively cover the whole surface in various shapes and inner side of
tubes170. Briefly, our model substrates, PU coupons, were immersed in a 1% solution
of tert-butylperoxy 2-ethylhexyl carbonate (TBEC) in isopropyl alcohol (IPA) for 2
hours at room temperature. After a few times of gentle wash with ethanol, the
coupons were transferred to a polymerization solution of 10% (weight ratio) PCBMA
macro-crosslinker containing 5 mM Fe(II) gluconate at 40°C for 12 h. In our control
study, 10% CBMA monomer, or 10% CBMA monomer with commonly used small
molecule crosslinker, N,N-Methylenebis(acrylamide) (MBAA), were used in the
polymerization solution to produce polymer brush coating or crosslinked coating,

64
respectively. Unreacted TBEC was removed by repeated gentle rinse with IPA. The
coupons with surface coatings were dried in vacuum before test.
The coating thickness was characterized by surface ellipsometry using the bare PU
surface as the control (Figure 4-3). Immediate after the coating reaction, the
macro-crosslinker coating showed much greater thickness (>300 nm) than the
polymer brush coating (11±1.3 nm), and the brush coating with MBAA crosslinker
(11.5±1.6 nm) at the same crosslinking density as macro-crosslinker (MBAA/CBMA
monomer ratio = double bonds unit/PCBMA unit). Under SEM, the coating for
polymer brush and the one crosslinked with MBAA could hardly tell, but the thick
coating of macro-crosslinker could be clearly visualized. Gel permeation
chromatography (GPC) characterization showed that the macro-crosslinker had an
average molecular of 174 KDa, which was much larger than the surface initiated
polymer brush (4.5 KDa). There were several reasons explaining the resulting low
MW of polymer brush. 1) There was steric hindrance between polymer brush chains
preventing the chain from growing larger171. 2) Surface redox polymerization was not
effective to produce high MW polymer since only monomer near the surface
participates the chain growth. 3) The presence of 5 mM Fe(II) gluconate, which was
the reducing agent to induce free radical generation on hydrogen peroxide of TBEC,
greatly decreased the solubility of zwitterionic monomer (maximum 18% by weight),
preventing further increasing the monomer concentration as a way to increase the
Mw of resulting polymer. Coating thickness from different methods was further
monitored after one week incubation in water. Polymer brush coating lost 80% of its
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thickness (from 10±1.2 nm to 2.1±0.2 nm) while macro-crosslinker coating was
almost intact (4 % thickness loss).
The durability of the surface coating made through different methods was further
examined by measuring water contact angles after different days of incubation in
water (Figure 4-4). Without any zwitterionic polymer coating, the bare PU surface
was hydrophobic showing a typically water contact angle around 70°. After the
coating through all tested methods, the contact angle decreased to around 8°,
indicating the efficient introduction of super-hydrophilic zwitterionic polymers onto
the PU surface. Nevertheless, as days went by, the contact angles for polymer brush
coating and polymer brush coating crosslinked by MBAA gradually increased and
reached the original contact angle of 70° (for bare PU) after two weeks. This suggests
that coatings were almost completely lost upon two weeks incubation in water.
Addition of small molecule crosslinker MBAA to mimic the same theoretical
crosslinking density of macro-crosslinker only led to negligible improvement in
durability. The contact angle for the macro-crosslinker coating, by contrast, remained
unchanged after one week and increased to 19° after two weeks, indicating greater
durability of this particular coating.
Zwitterionic material coatings were known for great non-fouling property that
resists non-specific protein binding and microorganism attachment, and can be
potentially applied on blood-contact biomedical devices, e.g., catheters, to resist
thrombosis and ship hulls to resist marine fouling. In these circumstances, coatings
would be subject to shear stress in the moving fluid such as blood and sea water; this
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required more durable coating technology to maintain long term anti-fouling
performance172. To test the durable function of the zwitterionic macro-crosslinking
coating under shear stress, the coating was exposed to PBS solution under 1500 rpm
stirring for one week and taken out for functional test. Human fibrinogen was utilized
for protein binding test and results before and after one week of flow condition were
compared (Figure 4-5). It was found that all coating methods were able to produce a
freshly-made coating that resists fibrinogen binding. However, after one week
exposure to flow condition, polymer brush coating and brush coating with MBAA
crosslinking lost anti-fouling function with protein binding returning to the level of
bare PU surface. The macro-crosslinker coating showed almost the same low level of
protein binding before and after the flow treatment, suggesting its superior
durability under shear stress condition. We further conducted bacterial attachment
assay as additional functional test for the coatings using E. coli. as a model bacterium.
After flow condition treatment in PBS, the coatings were transferred to high
concentration bacteria suspension (1.12*109 cell/ml) for 0.5 h, followed by repeated
washes with sterile PBS, fixation, dehydration and vacuum drying. The bacteria
attached on the coating surface were visualized under SEM and their density was
calculated (Figure 4-5). Similar results were obtained to the protein adsorption test.
After one week flow condition, the macro-crosslinker coating had almost zero
bacteria adhesion, but coating of polymer brush and the brush with MBAA
crosslinking showed bacterial adhesion as worse as bare PU surface.
So far many coating methods using zwitterionic materials were able to modify
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hydrophobic substrate with non-fouling property. However, these coatings were
usually vulnerable with only short-term function, since super-hydrophilic polymer
chains would be easily washed away by aqueous environment. It is obvious that
crosslinking individual polymer brush chains could help stabilize the overall
coatings173. In a crosslinked surface network, if one polymer chain tended to be torn
away from the surface, its neighbouring covalently linked polymers would retain it
from dissolving into water environment. Our results showed that different
crosslinking strategies had different levels of stabilizing effect on the coatings (Figure
4-6). What we found was small molecule crosslinker MBAA did not improve stability
of polymer brush, and the resulting crosslinked coatings was far less durable than
macro-crosslinker coatings. This could be potentially explained by 1) low local
concentration of MBAA (at the kept CBMA/MBAA ratio) led to relatively inefficient
crosslinking and 2) the monomer concentration could not be further increased in
presence of Fe(II) gluconate. We did observed that the small crosslinker MBAA
strategy was inefficient to further increase the coating thickness (11.5±1.6 nm)
compared with macro-crosslinker strategy (>300 nm). A thicker coating has generally
shown enhanced durability174.
In

summary,

we

demonstrated

the

synthesis

of

novel

zwitterionic

macro-crosslinker enabling the formation of durable non-fouling coating on common
hydrophobic plastic substrate, PU. Coating formed using the macro-crosslinker
exhibited much greater thickness and durability compared to common polymer
brush coating and brush coating crosslinked with small molecule crosslinkers. Upon
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incubation in water, macro-crosslinker coating was able to sustain hydrophilicity for
more than two weeks. Even under shear flow condition, the macro-crosslinker
coating was able to retain its non-fouling property to resist protein and bacteria
adsorption after one week treatment, while all other methods failed. The durable
zwitterionic macro-crosslinker coating can be potentially applied on blood-contact
biomedical devices or for marine coating applications.
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Figure 4-1 Synthetic route and 1H-NMR characterization of the macro-crosslinker
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Figure 4-2 1H-NMR of PCBMA macro-crssolinker with different double bond density
(labeled by CBMA/double bond molar ratio).
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Figure 4-3 (a) Coating thickness of different methods and (b) SEM image of
macro-crosslinker coating
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Figure 4-4 (a) Time course contact angles for coating surfaces made from different
methods and (b) water drop on macro-crosslinker coating on day 8
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Figure 4-5 (a) Protein binding test on coatings obtained from different methods
before and after one week exposure in flowing PBS, and E. coli adhesion test on
coatings obtained from (b) bare PU, (c) PCBMA brush coating, (d) PCBMA+MBAA
brush coating and (e) PCBMA macro-crosslinker coating with (f) calculated adhesion
density
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Figure 4-6 Mechanism of (a) fragile brush coating and (b) durable macro-crosslinker
coating.
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CHAPTER 5. SUPER-DURABLE COATING FABRICATED FROM A DOUBLE-SIDED TAPE
WITH LONG TERM “ZERO” BACTERIAL ADHESION
5.1 Introduction
In this Chapter, we will describe a novel durable zwitterionic polymers coating that
for the first-time potential addresses the tough biofilm issue. The novel coating can
be applied on many common substrates as easy as a double-sided tape. Simply apply
superglue on a given surface, apply the coating tape we developed on top, remove
the tape liner, and then the coating is obtained. The novel coating shows the
toughness and durability that have not yet been achieved by any reported one. Most
remarkably, this coating achieved unprecedented capability to resist biofilm.
State-of-the-art anti-fouling coatings started to accumulate bacteria after just a few
hours of contact and would be covered with dense biofilm usually in less than 7 days.
Our coating was able to achieve almost “zero” bacteria adhesion even after
one-month continuous contact with high concentration bacteria. Our coating
technology is convenient to apply and can promisingly solve the biofilm threat,
which deteriorates public health and impedes the function of most biomedical
devices.
There is no coating technology currently available that can prevent the notorious
biofilm formation issue175-176, which induces infections177-179 and impede device
function117, 180. The state-of-the-art anti-biofilm coatings are complex to fabricate
and poor in performance due to instability in working environment47. They usually
started to accumulate bacteria after immediate contact and would be covered with
dense biofilm usually within ~7 days45-46, 48, 181. Here, we report the first ever solution
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to fully address this tough biofilm issue by developing an easily-applied
super-antifouling coating. Our coating was able to achieve almost “zero” bacteria
adhesion even after one-month continuous contact with high concentration
bacteria.
Our novel Durable and Ultra-Robust Antifouling Zwitterionic (DURA-Z) coating
combined the use of a zwitterionic hydrogel tape (a double-sided tape) and
commercial superglue, and can be easily fabricated and universally applied on
common substrates. Super-hydrophilic zwitterionic polymer materials are known for
their superior antifouling properties182. But they, like common hydrophilic coatings,
drastically tend to dissolve in the aqueous environment resulting in poor coating
durability166, 168. The vulnerability to mechanical damages further prevents these
hydrophilic coatings from being practically applied183. Superglue based on ethyl
cyanoacrylate is one of the strongest linkages ever known for daily bonding projects,
and is known to only glue hydrophobic materials such as metal, plastic or wood. It
cannot stably bind to hydrophilic ones, e.g., glass slide which has a water contact
angle of ~28°. Against this conventional wisdom, here we were able to immobilize a
super-hydrophilic DURA-Z gel network (water contact angle < 2°) with the
hydrophobic superglue, through a unique interpenetration mechanism. The obtained
DURA-Z coating was super-hydrophilic and retained anti-fouling property after
various long-term durability tests in aqueous environments by incubating (90 days),
shearing (50 days) and flushing (30 days), as well as mechanical damage tests by
knife-scratch and repeated sandpaper abrasion at 570 kPa. The pressure used in our
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abrasion test is more than 150 times higher than other similar tests for coating
stability184. Remarkably, DURA-Z coating was able to achieve almost “zero” bacteria
adhesion for at least one month when continuously incubated with highly
concentrated bacteria (> 109 cells per ml) in culture media at both dynamic and static
conditions. This remarkable anti-biofilm performance has rarely been achieved.
DURA-Z coating can be easily removed from the substrate and re-applied, which
further extends the applicability of this coating strategy.
5.2 Materials and methods
5.2.1 Materials
Polyurethane coupons were purchased from BioSurface Technology. Stainless
steel strips were purchased from McMASTER-CARR. All solvents and chemicals were
purchased from Sigma-Aldrich and were used as received.
5.2.2 Fabrication of DURA-Z tapes.
DURA-Z tapes were fabricated by in-situ forming of a thin layer of PCBAA hydrogel
on

commercially

available

polypropylene

liner.

Briefly,

5

mg

2-Hydroxy-4’-(2-hydroxyethoxy)-2-methylpropiophenone (I-2959) initiator and 30
mg N,N’-Methylenebis(acrylamide) (MBAA) crosslinker were dissolved in 10 ml DI
water. 300 mg CBAA monomer was then dissolved in 300 µl initiator/crosslinker
solution to prepare a pre-gel solution, which was transferred to between two
polypropylene liners adhered to glass slides separated with a Teflon spacer (1 mm in
thickness). UV was applied for a few minutes to crosslink the PCBAA hydrogel.
DURA-Z tapes were obtained by removing the hydrogel layer along with the liners
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from glass slides.
5.2.3 Fabrication of DURA-Z coating.
The polyurethane (PU), stainless steel, glass and wood substrates were cleaned
with alcohol and dried in air (wood and metal were pre-treated by sandpaper to
obtain rough surfaces, and glass was pre-coated with a thin layer of EVO-stik glue).
Then one drop of cyanoacrylate superglue (ACE Hardware Corp.) was applied onto
the dried substrate, followed by pressing the DURA-Z tape (hydrogel layer facing
down) onto the superglue for a few seconds. One hour was then allowed to
completely solidify the superglue. The liner on top of the hydrogel was removed, and
the glued coating was transferred to DI water for equilibrium. 20 mins later, the
DURA-Z coating was polished either by a small shovel or tweezer, leaving the surface
with a thin layer of coating.
5.2.4 Scanning Electron Microscope (SEM) imaging.
samples were dried in vacuum and then coated with nano-gold using an SEEVac
Conductive IV sputter coater before imaged by a JSM - 6510LV SEM. For sectional
imaging, all tested coupons (bare PU, superglue coated and DURA-Z coated
substrates) were vertically cut into half using a sharp scalpel to expose the
cross-section.
5.2.5 Atomic-force Microscopy (AFM) imaging
AFM imaging of the bare PU, superglue coated and DURA-Z coated substrates was
conducted on a Dimension 3100 AFM from VEECO. All samples were vacuum dried
before imaging. The coating thickness and morphology were measured in the air
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through the tapping mode using silicon probes (VEECO) with a nominal frequency of
150 kHz. The AFM images were analyzed using Nanoscope software version 5.12.
5.2.6 Infra-red (IR) characterization
Bare PU, superglue coated and DURA-Z coated substrates were vacuum dried
before testing. PCBAA hydrogel was freeze-dried before testing. All samples‘ surfaces
were characterized on a NICOLET 6700 IR (Thermo Electron Corporation) equipped
with an attenuated total reflectance (ATR) accessory.
5.2.7 Contact angle
The water contact angle on bare PU, superglue coated and DURA-Z coated
substrates was conducted using a KSV contact angle instrument equipped with a
camera at room temperature and ambient humidity. 2 μl of water was dropped on
different surfaces and water contact angle was calculated using by the CAM2008
software.
5.2.8 Durability tests in aqueous environment
PBS shearing was created on a stirring plate by a 5-cm stirring bar at 1500 rpm in a
beaker (D = 10 cm). The tested samples were firmly clamped and positioned at the
inner wall of the beaker, and subjected to the continuous shear stress of 202 G. Body
temperature (37 °C) was controlled by the stirring plate and DI water was added to
compensate the evaporation every day to maintain standard PBS concentration. In
water flushing test, water was cycled by an electric pump with a flow rate of 42.8
ml/s. Protein adsorption test was conducted on the samples before and after the
durability challenge.
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5.2.9 Mechanical damage tests
For the knife-scratch test, DURA-Z coating on PU coupon was randomly cut by a
sharp scalpel. The abrasion test was conducted on an INSTRON compressor
equipped with a precise loading detector. Sandpapers (Gator waterproof sanding
400 grit) were fixed on both sides of the compressor and the pressure was calculated
by the loading divided by the area of PU coupon. One cycle of abrasion contains
pushing and pulling the coupon for 1-cm displacement back and forth under a given
pressure. The samples were subjected to 20 cycles of abrasion. Water wettability
and protein adsorption tests were conducted on the samples before and after the
mechanical damage challenge.
5.2.10 Protein absorption test (ELISA)
Human fibrinogen (Fg, Sigma-Aldrich) adsorption on a variety of substrates (bare
substrates, superglue coated and DURA-Z coated substrates) was measured using
ELISA method. All samples were incubated with 1mg/ml Fg for 10 minutes at room
temperature, followed by 5 washes with PBS buffer. They were then incubated with
1 mg/ml bovine serum albumin solution for 10 minutes at room temperature with 5
washes again with PBS buffer. The samples were removed from the fifth PBS wash
and transferred to new wells. They were next incubated with a 1:200-dilution of
horseradish peroxidase (HRP)-conjugated anti-fibrinogen (USBiological, Life Sicences)
in PBS for 10 minutes, followed by another 5 washes with PBS buffer. After the fifth
wash, the samples were transferred to new wells and SIGMAFAST OPD
(Sigma-Aldrich) was added to each well. They were incubated in the OPD solution for

81
30 minutes in the dark. The supernatant was removed from each test well,
transferred to a 96-well plate, and its absorbance at 490 nm was measured using a
UV-VIS spectrometer (Thermo Scientific Multiscan Go). All samples were measured
in triplicate.
5.2.11 Biofilm resistance of DURA-Z coating.
E. coli bacteria were cultured for 24 h at 37 °C on Luria-Bertani (LB) agar plates.
One colony was picked and cultured in 20 mL of LB broth medium overnight at 37 °C
on a shaker (Standard Analog Shaker, VWR) at 200 rpm. The resulting culture was
used to inoculate a second culture in 50 mL of LB medium until an optical density
(OD) of 0.8 at 600 nm was reached. The bacteria were collected by centrifugation at
8,000 x g for 10 min at 4 °C, washed three times with sterile PBS (pH 7.4) and finally
suspended in LB broth to get a final concentration of 1.05×10 9 cells per ml (OD = 1.31
at 600 nm) for biofilm formation test. In the dynamic method, PU (stainless steel,
wood, and glass) substrates, superglue coated substrates and DURA-Z coated
substrates were placed in bacterial culture medium (LB Broth) containing highly
concentrated bacteria (1.05×109 cells per ml) at 37 °C for 30 days under continuous
shaking (300 rpm). The culture medium was gently refreshed every two days, and
the bacterial density within the refreshed medium was kept at 1.05×10 9 cells per ml.
In the static method, PU substrates, superglue coated substrates and DURA-Z coated
substrates were stationarily placed in bacterial culture medium (LB Broth) containing
highly concentrated bacteria (1.05×109 cells per ml) at 37 °C for 30 days. Bacteria
were allowed to settle on the surface of the substrates through gravity. The culture
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medium was gently refreshed day by day, and the bacterial density within the
refreshed medium was kept at 1.05×109 cells per ml. After long-term incubation, all
substrates were rinsed with PBS for 30 mins (samples tested in the static method
were also imaged without rinsing). After the challenging periods, the substrates were
then immersed in the fix solution of 2.5% glutaraldehyde, 2% paraformaldehyde in
0.1 M sodium phosphate buffer and were then dehydrated in a gradient ethanol
series and dried in vacuum before SEM imaging. Adhered bacteria density was
counted by averaging 6 randomly selected areas (100 µm2 each).
5.3 Results and discussion
The formation of DURA-Z coating involves the combined use of a fabricated
double-sided DURA-Z tape and superglue obtained from the hardware store. DURA-Z
tape was prepared by the in-situ growing of a thin layer of zwitterionic
poly-carboxybetaine

acrylamide

(PCBAA,

3-((3-acrylamidopropyl)

-dimethylammonio)-propanoate) hydrogel on a commercial polypropylene (pp) liner
(Figure 5-1(a)). The fabricated hydrogel tape was mechanically stronger than the
pure zwitterionic PCBAA hydrogel and can withstand pulling, bending, wrenching
and rolling up (Figure 5-1(b)). This ensures ease of storage, transport, and mounting
of the DURA-Z tape on substrates to be coated. The fabricated DURA-Z tape can be
directly mounted as a coating layer without further treatment.
The DURA-Z coating can be glued on a variety of substrates through a simple
procedure (Figure 5-1(c)). Briefly, a substrate was firstly cleaned, e.g., the
polyurethane (PU) substrate was rinsed with alcohol and dried in air. Then one drop
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of cyanoacrylate superglue was applied onto the dried substrate, followed by
pressing the DURA-Z tape (hydrogel layer facing down) onto the superglue for a few
seconds. One hour was allowed to completely solidify the superglue. The liner on top
of the hydrogel was removed, and the glued coating was transferred to DI water for
equilibrium. 20 mins later, the DURA-Z coating was polished either by a small shovel
or tweezer, leaving the surface with a thin layer of coating.
The resulting DURA-Z coating showed completely different morphology compared
to PU substrate or cyanoacrylate superglue surface under Scanning Electron
Microscope (SEM, Figure 5-2(a)), and Atomic-force Microscope (AFM, Figure 5-3).
SEM images on coating cross-section provided structural details of a surface
hydrogel layer and a hydrogel/glue interpenetrating layer (Figure 5-2(a)). The overall
thickness of the coating (two layers) was measured to be 324±13 µm. The surface of
the DURA-Z coating was characterized by Infrared (IR) spectroscopy and showed
almost the same chemical composition as pure zwitterionic PCBAA hydrogel (Figure
5-2(c)). This implied the surface of the DURA-Z coating had superior anti-fouling
property as good as a zwitterionic hydrogel. Water contact angle (Figure 5-2(b))
indicated that DURA-Z coating was super-hydrophilic with great wettability (water
drop spread out quickly), similar to pure PCBAA hydrogel surface.
Super-hydrophilic polymer coatings were known to be unstable since polymers
drastically tended to dissolve in water. Common hydrophilic coatings would fail
within a few weeks in an aqueous environment. We incubated the DURA-Z coating in
DI water at room temperature for up to three months. The morphology of the
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coating was almost unchanged, and anti-fouling property (tested by human
fibrinogen binding followed by ELISA quantification of the absorbed protein) was
retained at the same level as freshly-made coatings after the long-term incubation
(Figure 5-4(a)). DURA-Z coating was further examined under various durability tests
in the water condition, including (1) exposed to PBS buffer shearing (1500 rpm,
202G) at room temperature for 50 days (Figure 5-4(b)), (2) exposed to PBS shearing
(1500 rpm, 202G) at body temperature (37 °C) for 30 days (Figure 5-5(a)), and (3)
subjected to continuous perpendicular water-flush at a flow rate of 42.8 ml/s for 30
days (Figure 5-5(b)). These challenging conditions did not change the morphology of
the DURA-Z coating, and the antifouling property of the coating was well retained,
indicated by the unchanged, significantly lowered human fibrinogen absorption on
the coating, compared with uncoated PU (Figure 5-5(a) and (b)).
The DURA-Z coating was further subjected to mechanical damage tests. We used a
sharp scalpel to randomly scratch the coating (Figure 5-5(d)). The coating retained its
small water contact angle and great anti-fouling property (Figure 5-5(d)). We further
examined the coating in an abrasion test, where a PU coupon with both sides coated
with DURA-Z was placed between two stationary sandpapers (400 grit) and a
pressure of 570 kPa was applied by a compressor (Figure 5-5(c)). The coupon was
moved back and forth (displacement = 1 cm) for 20 circles and the coating was found
to survive this abrasion test with great water wettability, and unchanged great
anti-fouling property (Figure 5-5(c)). It should be noted that the 570 kPa pressure
used in our abrasion test is more than 150 times higher than other similar tests for
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coating stability. In our sandpaper abrasion test, a PU coupon without DURA-Z
coating applied cannot be moved by manpower under a pressure of 50 kPa. It
appears that the slippery surface of DURA-Z coating contributes to its great
capability to resist abrasion damage.
Microorganism attachment on surfaces leads to biofilm formation that causes
medical device failure, infection and marine fouling related fuel penalty. Hydrophilic
polymer coatings, such as zwitterionic polymers, are non-toxic and environmentally
friendly and have shown their effectiveness in resisting microorganism
adhesion185-187. Nevertheless, due to the instability of hydrophilic polymers in an
aqueous environment, these coatings were not able to maintain the resistance to
microorganism adhesion for a longer period of time. Here we expect the
ultra-durable and robust DURA-Z coating can greatly improve long-term
microorganism resistance performance. To highlight this property, we utilized
Escherichia coli (E. coli) as a model system to study the coating’s resistance to biofilm
formation and quantified the bacterial adhesion by SEM. Our initial study has
challenged the coating with dynamic bacterial culture condition. DURA-Z coated PU
substrate was placed in bacterial culture medium (Luria-Bertani Broth) containing an
extremely high number of bacteria (1.05×109 cells per ml) at 37 °C for 30 days under
continuous shaking (300 rpm). The culture medium was gently refreshed every two
days, and the bacterial density within the refreshed medium was kept at 1.05×10 9
cells per ml. After 30 days, bacteria on the substrate surface were fixed, dehydrated,
vacuumed and visualized under SEM. Results indicate almost zero adhesion of
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bacteria on the zwitterionic DURA-Z coating, while biofilm had developed on the
bare PU substrate and the superglue coated surface (Figure 5-6 (a) and (b)).
We further challenged the DURA-Z coating with one of the harshest condition,
where high-density bacteria (1.05×109 cells per ml) were stationarily cultured with
the substrate in LB broth at 37 °C, and allowed to settle on the substrate surface
through gravity. The culture medium was gently refreshed day by day, and the
bacterial density within the refreshed medium was maintained at 1.05×10 9 cells per
ml. After 30 days, without any rinsing, only a small amount of bacteria was found to
be scattered on DURA-Z coating (no biofilm forming) under SEM (Figure 5-7). With
30 min of rinsing in PBS, these scattered bacteria were easily washed off from the
DURA-Z coating (Figure 5-6(c) and (d)). By contrast, a biofilm (high-density bacteria
adhered) formed on the bare PU substrate and superglue coated substrate, and
remained to be firmly attached even after rinsing (Figure 5-6(c) and (d)). It should be
noted that long-term biofilm resistance was highly desirable to reduce infection and
extend medical device lifetime, but remained a challenge in the field188. We attribute
the observed remarkable long-term biofilm resistance to the combined effect of
ultra-low fouling property and ultra-durability of the zwitterionic DURA-Z coating.
The DURA-Z coating can be easily applied to a variety of substrates including
stainless steel, wood, and glass (Fig. 5-8(a)) by combining the use of DURA-Z tape
and superglue. It should be noted that the glass substrate was pre-treated with a
thin layer of EVO-Stik glue before applying the coating due to the low affinity
between cyanoacrylate superglue and glass. DURA-Z coatings obtained on these
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substrates were also found to be durable as indicated by unchanged great
anti-fouling property even after two months of incubation in water (Figure 5-9). They
were also tested for E. coli biofilm resistance for 30 days using dynamic bacterial
challenge condition. Almost zero bacteria adhesion was achieved on all tested
DURA-Z coatings despite different types of substrates were coated (Figure 5-10).
Practically speaking, it is frequently desirable that a coating layer can be fully
removed from the substrate, followed by a new coating to be re-applied
seamlessly189. However, reapplication of coating was hard to realize based on the
chemical modification methods190-192 without significantly damaging the original
substrates. Here the DRUA-Z coating binds with the substrate surface through
commercial superglues which are dissolvable in organic solvents. Take DURA-Z
coated stainless steel for example (Figure 5-8(b)), upon 1-hour incubation in acetone,
the coating came off spontaneously without any damage to the substrate surface. It
is feasible to re-apply a new DURA-Z coating on this same stainless steel substrate,
and the new coating resisted protein binding as efficient as when it was first applied
(Figure 5-8(c)).
The key for the DURA-Z coating to achieve the ultra-durability is because of the
use of superglue to strongly bind the super-hydrophilic polymer network (PCBAA
hydrogel) and a hydrophobic substrate together. This is against common sense since
commercial superglue is known to only bind hydrophobic substrates. Superglues are
based on the rapid solidification of hydrophobic cyanoacrylate polymers, which have
low affinity with hydrophilic materials such as zwitterionic polymers. In fact, we tried
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to glue linear zwitterionic PCBAA polymer powder and highly concentrated
PCBAA/water solution on substrates using superglue, but the attached polymers
quickly dissolved upon incubation in water and both obtained surfaces showed
hydrophobic nature (Figure 5-11). The success of using superglue to strongly bind
hydrophilic zwitterionic hydrogel layer (DURA-Z coating) is attributed to the unique
inter-penetration structure formed between these two (Figure 5-2(a) and (d)). It is
expected that during the curing process, liquid cyanoacrylate monomers penetrated
into the zwitterionic hydrogel network and were crosslinked. The entanglement
between the DURA-Z and superglue networks immobilized the coating on the
substrate for as long and strong as the superglue adhesive can last.
For biofilm resistance performance, DURA-Z coating is unprecedented.
State-of-the-art anti-fouling coatings started to accumulate bacteria after just a few
hours of contact and would be covered with dense biofilm usually within ~7 days.
DURA-Z coating was able to achieve almost “zero” bacteria adhesion even after
one-month continuous contact with high concentration bacteria. This coating
technology is convenient to apply and can promisingly solve the biofilm threat,
which deteriorates public health and impedes the function of most biomedical
devices.
In summary, we developed an ultra-durable and robust zwitterionic polymer
network coating, namely DURA-Z, by combining the use of commercial superglue
and the developed DURA-Z tapes. DURA-Z coating showed great stability and
durability in a series of long-term challenges in aqueous environments as well as
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mechanical damage tests. With superior anti-fouling and durable property, the
coating was able to achieve almost zero adhesion of bacteria after one-month
continuous co-culture with E. coli bacteria at extremely high density. DURA-Z coating
is applicable to various common substrates to achieve long term durability and
anti-fouling performance, and when needed, it can be easily removed and re-applied.
This simple and inexpensive method will find applications as anti-fouling coatings in
large, such as anti-biofilm coatings, medical device coatings and marine coatings.
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Figure 5-1 (a) structure of DURA-Z tape, (b) DURA-Z tape under pulling, bending
wrenching and rolling, and (c) fabrication of DURA-Z coating on PU substrate.

Figure 5-2 (a) SEM imaging on the surface and sectioning of uncoated PU, superglue
and DURA-Z coated substrates (scale bar = 100 μm), (b) water contact angles on bare
PU, superglue and DURA-Z coated substrates, (c) IR spectra of bare PU surface,
superglue coated PU surface, DURA-Z coated surface and zwitterionic PCBAA
hydrogel surface, and (d) illustration of the formation of DURA-Z coating.
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Figure 5-3 AFM images of bare PU substrate, superglue and DURA-Z coated PU
substrates. Scale bar = 50 µm.

Figure 5-4 Antifouling property of DURA-Z coating after durability tests. (a) 3-month
incubation in water and (b) 50 days exposure to PBS shearing at room temperature.
Data were showed as mean of replicates (n=3) ± standard deviation. Statistical
analysis: unpaired, two-tailed t-test, n.s.: no significant difference at P > 0.05,
meaning the great anti-fouling property was retained.
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Figure 5-5 Antifouling property of DURA-Z coating after various durability and
mechanical damage tests. (a) 30 days exposure to PBS shearing under body
temperature, (b) 30 days exposure to perpendicular water flush, (c) 20 cycles of
abrasion test under 570 kPa, and (d) random scratch by a scalpel. The antifouling
property was evaluated by the resistance of human fibrinogen binding on the
surface (absorbed protein) before and after the coating being challenged. All data
were showed as mean of replicates (n=3) ± standard deviation. Statistical analysis:
unpaired, two-tailed t-test, n.s.: no significant difference at P > 0.05, meaning the
great anti-fouling property was retained.

Figure 5-6 representative SEM images of bacteria adhesion on bare PU, superglue
and DURA-Z coated PU substrates after 30 days of co-culture with E. coli bacteria at
(a) shaking condition and (b) static condition. Attached bacterial density was
calculated for (c) shaking condition and (d) static condition. ***: All data are
presented as mean of biological replicates (n=6) ± standard deviation. Statistical
analysis: one-way ANOVA with Bonferroni multi-comparison. ***: p < 0.0001. Scale
bar = 5 μm.
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Figure 5-7 representative SEM images showing bacteria adhesion on DURA-Z coating
after 30 days of culture with bacteria at static condition without any rinsing. Scale
bar = 5 µm.

Figure 5-8 (a) DURA-Z coating on wood, stainless steel, and glass substrates. (b) Easy
removal and re-application of DURA-Z coating on stainless steel substrate, and (c)
corresponding antifouling property. All data were showed as mean of replicates
(n=3) ± standard deviation. Statistical analysis: unpaired, two-tailed t-test, n.s.: no
significant difference at P > 0.05.
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Figure 5-9 Antifouling property of DURA-Z coating on wood, stainless steel and glass
substrates after two-month incubation in water. All data were showed as mean of
replicates (n=3) ± standard deviation. Statistical analysis: unpaired, two-tailed t-test,
n.s.: no significant difference at P > 0.05, meaning the great anti-fouling property
was retained.
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Figure 5-10 (a) representative SEM images of bacteria adhesion on wood, stainless
steel, glass and DURA-Z coating on these substrates after 30 days of co-culture with
bacteria at shaking condition, and (b) calculated bacterial density on wood, stainless
steel, glass and DURA-Z coatings on these substrates. All data are presented as mean
of biological replicates (n=6) ± standard deviation. Statistical analysis: unpaired
two-tailed t-test, ***: p < 0.0001. scale bar = 10 µm.

Figure 5-11 (a) PCBAA polymer powder and (b) PCBAA water solution were glued on
PU substrates. The coated surface showed hydrophobic nature after incubation in
water, as indicated by the non-spread water droplet.

96
CHAPTER 6. CONCLUSION AND OUTLOOK
The focus of this thesis is to study the potentials of the zwitterionic PCB materials
in solving several key challenges in various applications as stabilizing materials for
nanoparticles, hydrogels, and surface coatings, respectively. Specifically, this thesis
involves the work of a one-step synthesis of zwitterionic polymer modified carbon
nanoparticles, pancreatic islets encapsulation by PCB hydrogel materials and
subsequent transplantation to achieve long-term diabetic reversal effect, and a
durable zwitterionic PCB polymer coating for various substrates to resist long-term
biofilm formation. These subjects are introduced separately in the following
paragraphs.
The study on the ultra-stable carbon nanoparticles was a novel strategy to
fabricate core-shell NPs with superior stability directly and solely from anti-fouling
zwitterionic polymers through single step of microwave heating. We found that Only
those zwitterionic polymers that are stable through high temperature microwave
heating can produce zwitterionic polymer shell-carbon core NPs, which can be
further purified through sucrose gradient centrifugation. The resulting nanoparticle
showed superior colloid stability in bio-relevant media and even the freeze-drying
conditions. We expect this green chemistry in making ultra-stable NPs can inspire
future functional NPs to be developed. These ultra-stable florescent carbon
nanoparticles will find applications in cell labelling and trackable drug delivery
systems.
The project on islet transplantation exhibited the first synthetic polymer material
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ever known promoting functional neovascularization as good as natural body system.
A zwitterionic carboxy betaine containing hydrogel was found to promote
vascularization at the subcutaneous (s.c.) site to the same density level as normal
tissue, and to maintain that high-level vasculature for at least 6 months. The newly
formed blood vessels were perfused and they approached the implanted zwitterionic
gel surface as close as below 20 micrometers away. Consequently, the zwitterionic
hydrogel was highly accessible by circulating blood, even after 5 months of
implantation. This finding was highlighted by using zwitterionic hydrogel in
encapsulating islets for the treatment Type 1 diabetes. The zwitterionic hydrogel
based novel system remarkably outperforms the state-of-the-art technology using
alginate encapsulating materials at highly challenging s.c. site. We expect, with
natural tissue-like blood accessibility, the zwitterionic hydrogel is a promising
platform to improve the long-term performance of most current implantable devices
to fight against various diseases.
For the study on tough and durable zwitterionic polymer coating to resist
micro-organism biofilm, we first developed a novel zwitterionic macro-crosslinker to
overcome the vulnerability of zwitterionic coating on common hydrophobic
polyrethane substrate. Coating formed using the macro-crosslinker exhibited much
greater thickness and durability compared to common polymer brush coating and
brush coating crosslinked with small-molecule crosslinkers. Upon incubation in water,
macro-crosslinker coating was able to sustain hydrophilicity for more than two weeks.
Even under shear flow condition, the macro-crosslinker coating was able to retain its
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anti-fouling property to resist protein and bacteria adsorption after one week
treatment. The durable zwitterionic macro-crosslinker coating can be potentially
applied to resist micro-organism adhesion on blood-contact biomedical devices or for
marine coating applications.
For the anti-biofilm purpose, the durability of the macro-crosslinker coating was
not enough. We then the developed a DURA-Z coating to further increase the
durability and toughness of zwitterionic coating that was able to resist long term
biofilm resistance. The DURA-Z coating can be easily and universally applied on
common substrates. Against conventional wisdom, commercial superglue only for
binding hydrophobic materials was used to strongly immobilize the super-hydrophilic
DURA-Z coating through interpenetration. The fabricated DURA-Z coating retained
anti-fouling property after 90 days of immersion in water, 50 days of buffer shearing
and 30 days of water-flushing, and after repeated knife-scratch and sandpaper
abrasion under 570 kPa. The DURA-Z coating achieved a rarely reported long-term
biofilm resistance: it remained almost "zero" bacteria adhesion after continuously
challenged by more than 109 bacterial cells per ml culture medium for 30 days. The
DURA-Z coating greatly extended the industrial application of zwitterionic polymer
coating by overcoming the durability and toughness challenges, and can be applied in
medical devices and marine coating to protect working surfaces from biofilm growth
for the long term reliable use.
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ABSTRACT
ZWITTERIONIC POLYMER MATERIALS FOR NANOPARTICLE STABILIZATION, CELL
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Based on the superior anti-fouling property, the zwitterionic materials had great
potential in applications such as medical implants, medical device coating, and
marine coating industry. This dissertation will focus on the applications of
zwitterionic materials in stabilizing carbon nanoparticles, as implantable devices and
durable coating on medical devices for long-term anti-microbial purposes. Chapter 2
of the thesis will discuss a simple method to synthesis carbon nanoparticles stabilized
by zwitterionic polymers. Chapter 3 of the thesis reports the use of zwitterionic
hydrogel to encapsulate islet of Langerhans to treat Type 1 diabetes. In Chapter 4 and
5, several methods were developed to improve the stability and durability of
zwitterionic anti-fouling coating. The improved coatings were able to address the
notorious biofilm issue on medical devices by resisting the bacteria adhesion for a
long term in highly concentrated bacteria culture media. These works greatly extend
the applicability of zwitterionic materials for long-term anti-fouling purposes.
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